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Mutations of LMNA gene, encoding the proteins Lamin A and C, are common causes of 
familial dilated cardiomyopathy (DCM), typically manifesting in association with cardiac 
conduction defects.	 LaminA/C regulate various nuclear functions, including gene 
transcription and chromatin organization. Most of human studies on LaminA/C so far were 
conducted on fibroblasts, while those focusing on cardiomyocytes (CMs) are scarce. Thus, 
we generated a human cardiac model of LMNA-dependent cardiomyopathy (LMNA-CMP) 
by differentiating CMs from induced pluripotent stem cells (iPSCs) carrying the K219T and 
R190W LMNA mutations (LMNA-CMs). In vitro, these cells recapitulate morphological 
features of DCM. RNA-sequencing experiments revealed profound differences between 
control and LMNA-CMs transcriptomes. Remarkably, the main cardiac sodium channel gene 
(SCN5A), was one of the most downregulated gene. Accordingly, electrophysiological 
studies in LMNA-CMs showed a significant reduction of the maximal upstroke velocity and 
the related properties of the action potential, accompanied by a reduction of the peak sodium 
currents and diminished conduction velocity. Functional experiments also revealed 
diminished contractile force in LMNA mutated cells. Biochemical studies	 confirmed the 
reduction of SCN5A gene, and its encoded protein Nav1.5, and showed an increased binding 
of LaminA/C to its promoter. A higher deposition of H3K27me3 marker, together with an 
increased binding of its catalysing complex PRC2, was also found at that genomic locus. 
Furthermore, 3D-FISH studies indicated a preferential localization of SCN5A gene at the 
nuclear periphery. Similar findings were obtained in relation to genes of the contractile 
pathways. Altogether, these data support a mechanism by which LaminA/C influence 
cardiac function by directly acting on transcriptional regulation of genes that control CMs 
functionality. Studies conducted on CMs from CRISPR/Cas9 gene-edited iPSCs proved the 
causality between the LMNA mutation and the observed phenotypes.  
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Finally, experiments for evaluating the efficacy of Remodelin molecule also demonstrated 
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ACTC1  α-cardiac actin gene 
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AP   Action potential 
APA   AP amplitude 
BAF1   Barrier-to-autointegration factor 1 
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Cav   Calcium channel 
CDM1/ 2  Cardiac differentiation medium 1/ 2 
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ChIP-seq  ChIP-sequencing 
CIM CVPCs induction medium 
cLADs Constitutive LADs 
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CX40 Connexin 40 gene 
CX43 Connexin 43 gene 
DamID  DNA Adenine Methylation-based Identification 
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DEFA4  Defensin alpha 4 gene 
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H3K9me2  Histone 3 lysine 9 dimethylation 
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INM   Inner nuclear membrane 
IP   Immunoprecipitation 
iPSC   Induced Pluripotent Stem Cells 
IKR   Rapid potassium current 
IKS   Slow potassium current 
INa   Sodium current 
IPA   Ingenuity Pathway Analysis 
Ito   Transient outward potassium current 
K+   Potassium  
LA Left atrium 
LAD Lamina-associated domains 
LAP2α Lamin associated polypeptide 2α 
LBR Lamin B receptor 
LC-MS Liquid chromatography-mass spectrometry 
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LEM LAP, Emerin, MAN 
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LMNA   Lamin A/C gene 
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LMNB1  Lamin B1 gene 
LMNB2  Lamin B2 gene 
LQTS3  Long QT syndrome type 3 
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LV   Left Ventricle 
MAD   Mandibular Dysplasia 
MAN   Matrin-3 
MPD	 	 	 Maximal	diastolic	potential	
MYBPC3  Myosin-binding protein-C gene 
MYH6   α-Myosin heavy chain 6 gene 
MYH7   α-Myosin heavy chain 7 gene 
Na+   Sodium 
NAT10  N-acetyltransferase 10 enzyme 
Nav    Sodium channel 
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NLS   Nuclear localization signal 
NPCs   Nuclear pore complexes 
NT   Nuclear transplantation 
ONM   Outer nuclear membrane 
PAT-ChIP  Pathology tissue chromatin immunoprecipitation 
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PBMNCs  Peripheral blood mononuclear cells 
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PURO   Puromycin 
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ROCKi  Rho-associated coiled coil kinase inhibitor (Y27632) 
RPKM   Reads Per Kilobase Million 
RV   Right Ventricle 
SCN5A  Sodium channel 5 A gene 
SCN10A  Sodium channel 10 A gene 
SCN11A  Sodium channel 11 A gene 
sgRNA  Single guide RNA 
SMT   Single molecule tracking 
SN   Sinus node 
SNPs   Single- nucleotide polymorphism 
STED   Stimulated emission depletion 
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TBX3   T-box transcription factor 3 gene 
TBX5   T-box transcription factor 5 gene 
TCAP   Titin-Cap 
TNNT2   Cardiac troponin 2 gene 
TNNC1   Cardiac troponin C1 gene 
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TRIM28  Tripartite motif containing 28 gene 
TRIM63  Tripartite Motif Containing 63 gene 
TrxG   Trithorax group 
TSS   Transcriptional Start Site 
TTN   Titin gene 
















6.1. Lamin A/C and Laminopathies 
 
Mutations in LMNA gene, encoding the nuclear proteins Lamin A and C, give rise to a 
phenotypically heterogeneous group of disorders collectively called Laminopathies. These 
manifest with many different clinical disorders, typically presenting with tissue-specific 
phenotypes, often overlapping. Based on their clinical manifestations, laminopathies may be 
grouped into those that affect the striated (cardiac/skeletal) muscle (i.e. Emery-Dreifuss 
Muscular Dystrophy and Dilated Cardiomyopathy type 1A), the adipose tissue (Familial 
Partial Lipodystrophy – FPLD and other lypodytrophies) and the peripheral nerves, or can 
give rise to multi-organ systemic syndromes, mainly associated with accelerated ageing (i.e. 
Hutchington-Gilford Progeria Syndrome atypical Werner Syndrome). Table 1 gives a 
summary of both tissue-specific and systemic syndromes caused by Lamin A/C mutations; 
the tissue-specific phenotypes are also graphically represented in the Fig. 1. 
 
Tissue-specific disorder Inheritance 
Cardiomyopathy, dilated, 1A AD 
Charcot-Marie-Tooth disease, type 2B1 AR 
Emery-Dreifuss muscular dystrophy 2 (EDMD2) AD 
Emery-Dreifuss muscular dystrophy 3 (EDMD3) AR 
Heart-hand syndrome, Slovenian type AD 
Muscular dystrophy, congenital AD 
Muscular dystrophy, limb-girdle, type 1B 
(LGMD1B) 
AD 
Malouf syndrome AD 
Familial partial lipodystrophy of the Dunnigan, 
type 2 (FPLD) 
AD 
 
Systemic-multiorgans disorder Inheritance 
Hutchinson-Gilford Progeria syndrome (HGPS) AD 
Restrictive dermopathy, lethal AD 
Atypical Werner syndrome AD 
Mandibular Dysplasia (MAD) AR 
Lipoatrophy with Diabetes, hepatic steatosis, 
hypertrophic cardiomyopathy and 




Table 1. Diseases caused by LMNA gene mutations, classified as tissue-specific (top) or systemic- multi-organs 







Figure 1. Schematic representation of tissue specific phenotypes due to LMNA mutations. 
(Adapted from (Worman 2012). 
 
In spite of this heterogeneity, cardiac defects are quite frequent in all laminopathic patients 
and represent one of the primary cause of death (Worman and Bonne 2007), strongly 
indicating the heart as a principal tangible site of Lamin A/C action. 
 
Mutations in Lamin A/C were first identified associated to Emery-Dreifuss Muscular 
Dystrophy (EDMD) in 1999 ((Bonne, Di Barletta et al. 1999); in general, EDMD is 
especially caused by missense mutations but also frameshifts and deletions have been found 
in affected subjects (Benedetti, Menditto et al. 2007).  
Beside the autosomal dominant, an X-linked form of the diseases also exists and is caused 
by mutation in the EMD gene, encoding the protein of the inner nuclear membrane, emerin 
(Bione, Maestrini et al. 1994). 
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At the clinical level, EMDM patients are usually normal at birth and in the first years of life; 
symptoms generally start to develop in the second decade of life with contractures first and 
subsequently dilated cardiomyopathy (DCM) with conduction defects. However, in patients 
with LMNA heterozygous mutations, clinical manifestations may range from those typical 
of EDMD to no phenotypic effect (Raffaele Di Barletta, Ricci et al. 2000). 
Subsequently LMNA gene was also described as candidate in Familial Partial Lipodystrophy 
(FPLD), Dunnigan variety (Speckman, Garg et al. 2000; Cao, Liang et al. 2013). This 
disorder is typically characterized by loss of adipose tissue from the extremities and 
accumulation of fat deposition in the head and in the neck. Patients also manifest insulin 
resistance, dyslipidaemia and diabetes.  
 The above-mentioned disorders are referred to tissue-restricted diseases; however, 
mutations in LMNA gene can also cause systemic multi-organs disorders, as the Hutchinson-
Gilford Progeria Syndrome (HGPS) (De Sandre-Giovannoli, Bernard et al. 2003; Eriksson, 
Brown et al. 2003), which can be considered one of the most severe LMNA-dependent 
disease. Premature senescence is the typical sign of HGPS, which is clinically characterized 
by postnatal growth retardation, midface hypoplasia, micrognathia, premature 
atherosclerosis, absence of subcutaneous fat, alopecia, generalized osteodysplasia with 
osteolysis and pathologic fractures. Patients usually appear normal at birth, but in one year 
all the symptoms become strongly evident. Death usually occurs at around 14.6 years of age 
and, progressive atherosclerosis of the coronary and cerebrovascular arteries represents the 
principal cause (Brown 1992). At molecular level, the LMNA mutation associated to HGPS 
causes the expression of an aberrant form of prelamin A, called progerin, that accumulates 
into the cell nuclei, dramatically affecting nuclear architecture and cellular functions. 
Progerin also increases progressively during “normal” aging but it is still not clear whether 




6.1.1. Lamin A/C-dependent Cardiomyopathy 
 
Mutations in LMNA gene were also shown to give rise to DCM, typically complicated by 
conduction system diseases, in absence or with minimal skeletal muscle involvement 
(Fatkin, MacRae et al. 1999). As of today, 165 unique mutations have been reported, 
distributed all along the entire gene (Tesson, Saj et al. 2014); however, most of the mutations 
occur in the head and in the rod domain, but rarely in the tail domain. The majority of the 
pathogenic variants are missense and nonsense mutations, while fewer are small deletions 
or small insertions or occur at the splicing sites; such variants exert their pathogenic action 
through either a haploinsufficiency or dominant-negative mechanisms (Dittmer, Sahni et al. 
2014; Zahr and Jaalouk 2018). 
From the clinical side, DCM is phenotypically characterized by enlargement of left ventricle 
(LV), with a decrease in contractile force and in blood pumping (Fig. 2). When DCM is due 
to LMNA mutations, the disease has a worse prognosis with a high penetrance (often age-
dependent) and young onset, and is characterized by an extremely high rate of heart 
transplantation due to heart failure and an increased risk of sudden cardiac death due to the 
occurrence of progressive conduction system diseases, such as atrioventricular block, 
bradyarrhythmias and tachyarrhythmias (Arbustini, Morbini et al. 2000; van Rijsingen, 





Figure 2. Representation of stylised human heart, anterior exposure. A normal Heart is illustrated on 
the left. The cartoon on the right schematically shows the morphological changes in patients’ DCM hearts. 
RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle. 
 
Although DCM has been reported associated to mutations in numerous genes, mostly 
sarcomeric, such as α-myosin heavy chain (MYH6 and MYH7), α-cardiac actin (ACTC1), 
cardiac troponins (TNNT2, TNNC1, TNNI3), mutations in those encoding the sarcomeric 
protein titin (TTN) and the nuclear lamina component Lamin A/C (LMNA) are considered 
the most frequent causes (McNally and Mestroni 2017). As a matter of fact, LMNA gene is 
the second most commonly altered gene associated to familial DCM, and accounts for ∼6-
8% of the cases (Hershberger and Siegfried 2011).  
Furthermore, as already specified above, cardiac abnormalities are also hallmark of other 
laminopathies, such as EDMD, Limb-girdle muscular dystrophy 1B (LGMD-1B) and 
HGPS. In this last case, even though DCM is occurring in progeria patients, the 
accumulation of progerin has not been specifically associated to this specific phenotype 
(McNally and Mestroni 2017). Therefore, progerin accumulation may not at the basis of 
premature aging disorders and DCM.  
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6.1.2. LMNA and LaminA/C: classification and biological functions 
 
LaminA/C belong to the family of the lamin proteins, which are classified as type-V 
intermediate filaments (IFs) and assemble to form the nuclear lamina (NL), a dense 
compartment of filamentous proteins involved in maintaining the nuclear architecture and 
anchoring DNA and chromatin to nuclear periphery. The mammalian cell predominantly 
expresses four lamins’ isoforms, grouped into A-type (A and C) or B-type (B1 and B2), that 
can be distinguished on the basis of their primary sequence (Herrmann and Aebi 2016), their 
chemical features (Gerace and Blobel 1980; Krohne and Benavente 1986) and their tissue-
specific expression (Harborth, Elbashir et al. 2001). In fact, whereas B-type lamins are 
ubiquitously expressed (Dittmer and Misteli 2011), A-type ones are mostly expressed in 
differentiated cells and absent, or expressed in reduced quantities, in early embryos, 
hematopoietic cells, certain neurons, undifferentiated epithelial and mesenchymal cells and 
few types of cancer (Worman and Bonne 2007).  The tissue-specificity and the timely-
regulated expression of LaminA/C is in favour of an important role of these proteins in cell 
differentiation and lineage determination (Worman and Bonne 2007; Butin-Israeli, Adam et 
al. 2012).  
LMNA gene is located on chromosome 1q21 and encodes two protein products, Lamin A 
and Lamin C, whereas Lamin B1 and Lamin B2 proteins are encoded by LMNB1 and 
LMNB2 genes, which are on chromosomes 5q23 and 19q13 respectively. As the other type-
V IFs, lamins share protein structure domains and amino acid sequence. These are 
characterized by a central rod domain, composed by four α-helical segments (1A, 1B, 2A 
and 2B), a short N-terminal head domain and a tail-domain to the C-terminal, with nine β-
strands in sandwich configuration (Fig. 3). The tail domain contains a nuclear localization 
signal (NLS), an Ig-fold like domain, and, with the exception of Lamin C, a carboxy-terminal 
CaaX domain, that is chemically modified by carboxymethylation and farnesylation, a 
posttranscriptional modification with an isoprenoid lipid to C-terminal region (Young, Fong 
et al. 2005). Whereas B-type Lamins remain farnesylated, Lamin A protein is subjected to 
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further processing by the zinc metalloproteinase Zmpste24/FACE1, which specifically 
cleaves the last C-terminal 15 residues of the farnesylated Lamin A (Prelamin A). The 





Figure 3. Schematic representation of Lamin proteins’ structure. A panel shows A-type Lamins, 
distinguishing Lamin A, with 664 aminoacid residues and CaaX site included in the C-terminal tail domain, 
from Lamin C, with 572 residues and lacking of CaaX site. In B, B-type Lamins are illustrated. They are highly 
similar for their sequence but encoded by two different genes. Protein structure is extensively conserved among 
the different types of Lamins, with a N-terminal head domain, a central α-helical rod domain and a C-terminal 
tail domain. 
 
Despite the preferential localization at the nuclear envelope, a small fraction of LaminA/C 
protein is also present at the nuclear interior. The nucleoplasmatic LaminA/C is 
characterized by an increased solubility and, as such, seems to be more dynamic; in this 
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compartment, its interaction with some chromatin binding-factors, as LAP2α, has been 
described, which is involved in the regulation of gene transcription and chromatin 





 6.1.3. LaminA/C and its binding partners 
 
The nuclear envelope (NE) is one of functional domain of the nucleus: it is composed by 
two membranes the “inner” (INM – inner nuclear membrane) and the “outer” (ONM – outer 
nuclear membrane), which are separated by a lumen region of 30-50 nm, or fuse together to 




Figure 4. Structure of the nuclear envelope. The inner nuclear membrane (INM) and the outer nuclear 
membrane (ONM) define the NE. These two membranes are always separated by the lumen, but they fuse 
together in nuclear pore complex (NPC).  
 
 
The INM and ONM are structurally and functionally different and establish interaction with 
several integral membrane proteins. Among these, A- and B-type Lamins are the most 
abundant and create an intricate filamentous network of interactions. Several studies 
reported more than 100 lamina associated polypeptides (LAP), identified through LC-MS 
analysis (Kubben, Voncken et al. 2010). Only 13% of the total number of interacting proteins 
were known to be Lamin A/C binding partners; those include: Barrier-to-autointegration 
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factor 1 (BAF1), emerin, matrin-3, MAN, titin, Lamin A, Lamin B, replication dependent 
and independent histones, lamin B receptor (LBR) and tripartite motif containing 28 
(Trim28). The LAP concept, already emerged in 1988 (Senior and Gerace 1988; Foisner and 
Gerace 1993), was used to described a subgroup of polypeptides with specific solubility 
features, but then expanded to other proteins with various characteristics, which are bound 
to Lamins with variable strength (Wilson and Foisner 2010) as: retinoblastoma (Rb), PCNA, 
c-FOS and OCT-1. In addition to the binding with proteins of the INM, the interaction 
between LaminsA/C and lamina-associated polypeptide (LAP) 2a (Dechat, Gajewski et al. 
2004) is quite relevant for LaminA/C regulatory function. LaminA/C- LAP2a complex 
exists as a detergent-soluble pool in the nuclear interior (Kolb, Maass et al. 2011) and the 
interaction between the two proteins is necessary to regulate the nucleoplasmatic localization 
of LaminA/C. Indeed, studies on LAP2a knock-out mice show absence of nucleoplasmic 
A-type lamins. Re-expression of the wild-type LAP2a into knock-out cells is sufficient to 
rescue the localization of LaminA/C in the nuclear interior (Naetar, Korbei et al. 2008). 
Some of the binding partners listed above share a protein domain, called LEM (LAP, 
Emerin, MAN) domain, which is a common motif composed by two α-helix motifs of 45 
residues. BAF protein can bind the LEM domain and can be used as a “bridge” to connect 
DNA or chromatin to lamina-associated proteins or to Lamins directly (Margalit, Neufeld et 
al. 2007).  
Interestingly, Polycomb Repressive Complex 1 and 2 (PRC1 and PRC2) have been recently 
added to the list of the lamin-binding partners (Cesarini, Mozzetta et al. 2015). In both, 
mouse model and in vitro studies using C2C12 cells, Lamin A/C was described as necessary 
scaffold to guarantee the proper formation of the polycomb bodies (Cesarini, Mozzetta et al. 
2015; Marullo, Cesarini et al. 2016). Furthermore, changing in gene positioning and 
chromatin relocalization were found in a EDMD mouse model, and were demonstrated to 
be a consequence of the impairment of LaminA/C – PRC2 interaction. While the pivotal role 
of PRC2 in regulating chromatin architecture and transcription is widely recognized, clear 
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evidence that elucidate the molecular mechanisms at the basis of the dynamic interaction 
between the two proteins are still missing. However, the recent studies describing the 
cooperation of PRC2 and LaminA/C represent a step forward in the understanding of their 
interplay in regulating gene transcription. 
 
 
6.1.4. The epigenetic role of Lamin A/C 
 
Besides its well-known structural role, LaminA/C is also a master player in regulating gene 
transcription through mechanisms involving chromatin organization and remodelling, DNA 
replication and signal transduction pathways (Gruenbaum, Margalit et al. 2005; Dechat, 
Pfleghaar et al. 2008; Dittmer and Misteli 2011). In addition to the numerous interactions of 
LaminA/C with specific proteins and/or transcriptional factors, already described the section 
6.1.3 of this Thesis, LaminA/C is also able to interact directly with chromatin, in regions of 
the genome defined as the Lamina-associated domains (LADs) (Pickersgill, Kalverda et al. 
2006). These regions have been firstly identified and mapped in D. melanogaster and C. 
elegans, and then were also discovered in the mouse and human genomes (Pickersgill, 
Kalverda et al. 2006; Guelen, Pagie et al. 2008; Ikegami, Egelhofer et al. 2010; Peric-
Hupkes, Meuleman et al. 2010), using the adenine methyltransferase technique (DamID) 
(Pickersgill, Kalverda et al. 2006). LADs are large genomic regions ranging from 0.1 to 10 
megabases (Mb) in size and their occupancy corresponds to more than one–third of mouse 
and human genome (Kind and van Steensel 2010; Meuleman, Peric-Hupkes et al. 2013). The 
majority of genes present in the LADs are expressed at very low level and possess several 
molecular characteristics of heterochromatin (i.e. low genes density and expression; 
H3K9me2, H3K9me3 and H3K27me3 histone marks enriched regions) (Fig.5) (Meuleman, 




Figure 5. Schematic representation of lamin-associated domains (LADs) in a eukaryotic nucleus. LADs 
are the large genomic regions interacting with the nuclear lamina (here indicated as a coil red line); these are 
flanked by H3K27me3 histone marker (purple portion), usually identifying those referred as variable LADs.. 
 
 
Genome-wide studies indicated the existence of different LADs, those that are conserved 
among cell-type, named constitutive LADs (cLADs) and others that interact with the NL in 
a cell-type specific manner, called facultative (or variable) LADs (fLADs or vLADs) (Peric-
Hupkes, Meuleman et al. 2010; Meuleman, Peric-Hupkes et al. 2013). cLADs are more 
conserved than fLADs, in terms of size and genomic position, among the species (mouse 
and human) and therefore form a structural ”backbone” that is crucial to determine the spatial 
architecture of chromosomes into the nucleus. Instead, fLADs change their genomic 
positions inside the nucleus: they mostly contain genes involved in development, and are 
subjected to remodelling during differentiation of mammalian cells, demonstrating the 
dynamics and flexibility of their interaction with the NL. These changes correspond to 
specific gene expression pattern: detachment from NL is typically associated to gene 
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activation, while attachment to the NL is accompanied by gene repression (Peric-Hupkes, 
Meuleman et al. 2010; Robson, de Las Heras et al. 2016). 
However, how LADs sequences determines the LaminA/C interactions is still enigmatic, but 
it seems to be linked to the chromatin state. The presence of some histone marks at the LAD 
regions (i.e. H3K9me2/me3; H3K27me3), suggests G9A, SUV39H1/H2 and EZH2 
enzymes, which catalyse these modifications, may be directly involved in orchestrating such 
NL-genome interaction (Bian, Khanna et al. 2013; Kind, Pagie et al. 2013; Chen, Yammine 
et al. 2014; Harr, Luperchio et al. 2015). 
 
6.1.5. The role of Lamin A/C in the Heart 
 
As already mentioned in the above sections of this thesis, cardiac involvement is very 
frequent in all laminopathies and manifest with cardiomyopathy associated with 
disturbances of the conduction, suggesting an important function of LaminA/C in the correct 
functioning of the heart. 
Besides, studies addressing the role of LaminA/C in the heart and in the cardiomyocytes, the 
contracting units within the heart, are still limited.  
Most of the knowledge we gained so far on functional and molecular mechanisms behind 
the cardiac phenotype in laminopathies comes from mouse models. In 1999, Sullivan and 
colleagues firstly generated a Lmna knockout (Lmna-/-) mouse. The homozygous null mice 
displayed the following major phenotypes: (i) retarded growth rate, (ii) reduced stores of 
white fat and (iii) cardiac arrhythmia (Sullivan, Escalante-Alcalde et al. 1999). These mice 
generally die by the fourth week after birth. At molecular level, increased of pro-adipogenic 
factors (PPAPγ and CEBP/α) and decreased of Wnt-10/β-catenin levels have been shown as 
result of LaminA/C lack (Tong, Li et al. 2011), supporting the hypothesis that LaminA/C 
can influence myogenesis and osteogenesis through regulating adipogenesis (Tong, Li et al. 
2011). Significant contributions to the understanding of the pathophysiology of cardiac 
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laminopathy have come from the H222P-Lmna transgenic mice (Arimura, Helbling-Leclerc 
et al. 2005). These mice showed cardiac conduction defects, dilatation of the heart chambers, 
increased fibrosis and lack of hypertrophy, due to elevated extracellular signal-regulated 
kinase 1/2 (erk1/2) (Chatzifrangkeskou, Le Dour et al. 2016). Moreover, Mounkes and 
colleagues generated a homozygous KI-Lmna N195K mouse model, which also 
recapitulated the DCM phenotype and exhibited disruption of the structural organization of 
the cardiomyocytes as misexpression and/or mislocalization of connexin 40 and connexin 
43 and loss of sarcomeres organization were observed (Mounkes, Kozlov et al. 2005). 
Although animal models have been necessary to significantly improve our knowledge on the 
genetics, the physiology and the molecular counterpart of lamin-dependent cardiomyopathy, 
human phenotypes may not be completely represented in mice, since numerous differences 
exist between the two species in the pathophysiology of the heart (discussed in detail in 
paragraph 6.2.6 of this Thesis). Therefore, studying the disease using animal models may 
not be exhaustive. On the other hand, studying cells from human heart has limitations, 
mainly due to the limited accessibility of the organs and the difficulty to maintain heart cells 
ex vivo, so that human studies have been limited so far to more accessible cell type, such as 
fibroblasts, skeletal muscle cells and adipocytes. 
The possibility to obtain cardiomyocytes (CMs) of human derivation in vitro may 
significantly improve our possibility to investigate disease-causing mechanisms and 
contribute to burst the development of new therapies.  
In 2004, Gaustad and colleagues provided evidence for the involvement of LaminA/C in 
determining specific lineage specification events for the differentiation of contractile tissue. 
They showed how human adipose tissue stem cells, which do not express LaminA/C, 
become able to differentiate into beating CMs after exposure to cell extracts from rat CMs, 
which instead express LaminA/C (Gaustad, Boquest et al. 2004). Based on diverse studies 
conducted on different cell types, several hypotheses have been raised to explain the 
molecular mechanisms at the basis of LaminA/C action in the heart. On one hand, LaminA/C 
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has been proposed to influence the structural architecture of the contractile tissue, conferring 
resistance and protection against mechanical stress (Swift, Ivanovska et al. 2013); this is 
probably due to the α-helical coiled coil structure assembled into rope-like fibres that 
typically confer mechanical resistance to tension. In addition to the “mechanical stress” 
theory described above, the softer nuclei’s structure caused by LMNA mutations can increase 
sensitivity to cell damage and apoptosis, and lead to an impairment in the nucleo-cytoskeletal 
coupling. This is referred as “structural hypothesis”, and identifies the morphological 
abnormalities of the laminopathic nuclei as the molecular events at the basis of the lamin-
dependent cardiac phenotypes (Nikolova, Leimena et al. 2004). Besides this “structural 
hypothesis”, a “gene expression” hypothesis has also been raised. This is based on the 
putative role of LaminA/C in regulating gene transcription and proposes these proteins as 
important regulators of tissue-specific gene expression. As of today, there are no clear 
evidence supporting one hypothesis more than the other. Further studies are necessary to 
deepen our knowledge on the complex molecular events driving onset and progression of 
cardiac disease in laminopathies and to unveil how LaminA/C protein interfere with CM 
function. 
On this regard, the advent of induced pluripotent stem cells (iPSC) has revolutionized the 
approached to the disease, allowing the generation of unlimited number of human CMs for 
any experimental need, in vitro. Few iPSC-based models of lamin-dependent 
cardiomyopathy have been reported in the last years that contributed to further improve our 
knowledge on the field. A detailed description of the aforementioned iPSC-models is 
provided in the section 6.2.8 of this chapter.  
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6.2. Induced Pluripotent Stem Cells (iPSCs) 
 
6.2.1. Cell Reprogramming: Concepts and Developments  
 
In 2006, Shinya Yamanaka, from Kyoto University, demonstrated for the first time the 
possibility to generate cells with a pluripotent potential from terminally differentiated cells, 
mouse adult fibroblasts, through the exogenous expression of four transcription factors  
(Oct3/4; Sox2; c-Myc; Klf4), identified over a 24 factors known to play an important role in 
maintenance of embryonic stem (ES) cell identity (Fig.6) (Takahashi and Yamanaka 2006). 
The derived pluripotent cells were called induced Pluripotent Stem Cells (iPSC) and marked 
the beginning of a new era for the investigation of human diseases. 
In fact, in 2007, iPSCs were also derived from human fibroblasts by two different groups, 
using either the previously four identified “Yamanaka factors” (Takahashi, Tanabe et al. 
2007) or a different cocktail of transcription factors, OCT4; SOX2; NANOG and LIN28 (Yu, 




Figure 6. Schematic representation of reprogramming process. Generation of iPSCs from patient specific 
skin fibroblasts: transduction of the somatic cells with the “embryonic” genes SOX2, OCT4, KLF-4 and c-MYC 




However, the concept that a somatic cell may acquire a pluripotent potential was not new at 
the time of iPSCs discovery; several important studies conducted in the previous decades 
demonstrated this possibility in different contexts, setting the ground that guided scientists 
in reaching this important milestone. The revolution of iPSCs lies in the ease of generation, 
which renders the technology accessible to many laboratories all over the world, and in the 
possibility to avoid manipulation of human embryos (and their derivates). 
In 1952 the concept of cellular reprogramming was firstly demonstrated by Briggs and King. 
They showed the developmental potential of nuclei isolated from frog cells at different 
stages of embryonic development, by transplantation into enucleated oocytes (Briggs and 
King 1952). The method was subsequently called nuclear transplantation (NT) or “cloning”. 
In their studies they observed a gradual decline in the cloning efficiency with the increase of 
differentiation of the donor-cell. A decade later, in 1962, Gurdon succeeded in generating 
adult frogs by nuclear transfer from embryonic cells (Gurdon 1962). 
The establishment of stem cells properties, namely the ability to self-renew and to 
differentiate into multiple lineages, dates back to the sixties, thanks to the studies of James 
Till and Ernest McCulloch on the hematopoietic system: they demonstrated that the injection 
of bone marrow cells into the spleen of irradiated mice was sufficient give rise to multiple 
lineage hematopoietic colonies (McCulloch and Till 1960).  
In the subsequent years, the relevant progresses in the field made possible to succeed in the 
cloning of mammals, from the “famous” sheep Dolly (Wilmut, Schnieke et al. 1997) to 
mouse and other mammals (Hochedlinger and Jaenisch 2002; Eggan, Baldwin et al. 2004), 
and in the derivation of embryonic stem (ES) cells of both, mouse (Evans and Kaufman 
1981) and human derivation (Thomson, Itskovitz-Eldor et al. 1998). These last achievements 
and the studies conducted on ES cells are of particular relevance for iPSC field of research, 
since ES cells represent the “gold standard” for pluripotency.  
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On the whole, those studies have led to understand that the genetic mechanisms behind 
cellular differentiation are completely reversible and that terminally differentiated cells 
(their nuclei) are genetically pluripotent. This concept reverses the developmental model, 
proposed by Conrad Waddington in 1957, which describes how undifferentiated cells 
acquire their terminally specialization by an unidirectional process (Fig.7-A). This concept 
was drawn as a ball (zygote) rolling down from the top of the hill to valleys of specialized 
adult cells, passing through distinct differentiation states (precursors and progenitors), with 
different epigenetic profiles (Waddington 1957).  
Cellular reprogramming can revert cells from a specific differentiated state back to an 
undifferentiated cell, which is defined pluripotent. The process of reprograming has been 
depicted as climbing the top of the hill, to highlight the complexity of the method and its 
low efficiency (Fig.7-B). The understanding of molecular events and epigenetic changes 
occurring during these processes can unveil how differentiated cells acquire their identity 
and a specific cell fate and provide us with more powerful tools to intervene in facilitating 





Figure 7. The Waddington model (Adapted from Waddington “The strategy of genes” 1957). The 
cartoon in the panel A represents the route of normal development from a totipotent state (zygote) to 
terminally differentiated one, the specialized cell. B panel illustrates the conversion of adult somatic cells 
back to pluripotent state; this is a forced process that involves numerous changing of the epigenetic 
profile.  The epigenetic status of the two different cell types is indicated in the middle. 
 
 
6.2.2. The epigenetics of reprogramming and iPSCs 
 
The reprograming process is mediated by subsequent epigenetic changes along distinct 
cellular states that can be summarized in: (i) the silencing of retroviral transgenes, when the 
pluripotency is establish, (ii) reactivation of endogenous pluripotency genes, (iii) 
establishment of the bivalent domains (presence of both H3K4me3 and H3K27me3) at the 
promoters of key developmentally-regulated genes, (iiii) DNA modifications as 
hypomethylation and hypermethylation of imprinted genes, (iiiii) reactivation of previously 
inactive X chromosome in female iPSCs (Kim, Doi et al. 2010). The multiple factors 
implicated in the reprogramming process are listed in the Table 2. 
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Table 2. Epigenetic mediators that influence the reprogramming efficiency. Chromatins modifications are 
reported in the first column, their catalytic enzymes in the centre of the table and functions are summarized in 
the right column. 
 
At the initial stage of the reprograming, cells are globally marked with H3K4me2. WDR5, 
a component of Trithorax group (TRXG) mediates the methylation of H3K4me2 into 
H3K4me3, a chromatin marker typically linked to transcriptional activation and that, in this 
stage, is found associated to the promoters of pluripotency genes (Watanabe, Yamada et al. 
2013), whereas Polycomb group (PcG) complex catalyses the try-methylation of K27 
residue on Histone 3, to repress the expression of developmentally-regulated genes (Lee, 
Jenner et al. 2006). These loci simultaneously marked with H3K4me3 and H3K27me3 are 
defined “bivalent domains” and preferentially mark promoters of developmentally regulated 
genes (Harikumar and Meshorer 2015); in addition to this peculiar mark, the H3K9me2/3 
demethylation, which is mediated by JMJD1A and JMJD2C and the high level of de novo 
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DNA methyltransferase activities, represent another characteristic epigenetic signature of 
iPSCs (Loh, Zhang et al. 2007).   
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6.2.3. Insight the strategy to induce iPSC 
 
Generation of iPSCs implicates a resetting of the epigenetic profile of the somatic cells of 
origin, as reported (Kim, Doi et al. 2010; Papp and Plath 2013). The expression of the 
“reprogramming” transcription factors promotes the establishment of an “epigenome” 
similar to that of ES-cells, by inducing expression of endogenous “pluripotency” genes and 
preventing expression of those involved in cell differentiation; the resulting reprogrammed 
cells, iPSCs, are indistinguishable from ES-cells for morphology and possess self-renewal 
and developmental potential as ES-cells (Smith 2001). 
Multiple approaches have been successfully employed for cell reprogramming; choice of the 
strategy mainly depends on the cell type and on the intended use. A major classification of 
the derivation methods relies on whether the integration of the transgenes into the host 
genome is occurring. The efficiency of the integrative approaches is typically higher (0.01% 
- 1%) than the non-integrative ones, but the random virus integration represents an issue 
since it can potentially alter the expression of genes, such as oncogenes. Thus, use of circular 
plasmids, non-integrative vectors or mRNA-based methods was employed to overcome this 
limit. The available reprogramming approaches are summarized in the Table 3. 
 
Integrative Methods -Retroviral vectors (Takahashi, Tanabe et al. 2007)  
-Lentiviral vectors (Blelloch, Venere et al. 2007; 
Yu, Vodyanik et al. 2007)  
-Excisable vectors (Kaji, Norrby et al. 2009; 
Woltjen, Michael et al. 2009) 
Non-integrative Methods Sendai virus-based vectors (Fusaki, Ban et al. 
2009) 
DNA free method Modified mRNAs (Warren, Manos et al. 2010) 






6.2.4. Characterization of iPSCs 
 
Following generation, a comprehensive characterization of the iPSCs lines is required in 
order to assess their actual pluripotency (International Stem Cell, Adewumi et al. 2007; 
Marti, Mulero et al. 2013). Various criteria are adopted to verify that iPSCs possess 
pluripotency-associated features: these mostly relies on assessment of their similarity to ES 
cells and include morphology, functionality and molecular ES cell-like characteristics 
(Fig.8). On regard of the morphological evaluation, iPSCs, must be round colonies with 
defined borders and display high nucleus/cytoplasm ratio with prominent nucleoli. Also, 
iPSCs possess alkaline phosphatase (AP) activity. 
At the molecular level, the expression of pluripotency transcription factors (NANOG, SOX2, 
OCT4 and others) and surface antigens typical of ES cells, as SSEA-3/4 and TRA-1-60 is 
required.  
At last, embryoid bodies (EBs) and teratoma formation assays represent the most stringent 
test in support of the full pluripotency of the generated iPSC lines, indicating they are able 
to differentiate into derivatives of the three germ layers. 
 
 
Figure 8. Workflow of iPSCs characterization. To verify the actual pluripotency of generated iPSC clones, 
specific assays are typically used: ES-like morphology, analysis of the expression of pluripotency markers (as 
TRA1-60, DNMT3B, OCT4, REX1 and SSEA4), Alkaline phosphatase activity, embryoid bodies and teratoma 




Under defined culture conditions, iPSCs can be cultured for many passages, even in feeder-
free conditions, while maintaining a normal karyotype. Furthermore, culturing iPSCs in a 
hypoxic environment at 5% tension of O2 has been shown to positively influence the cellular 
reprogramming, by increasing the efficiency of the process, and to favour their genomic 
stability (Yoshida, Takahashi et al. 2009). 
 
 
6.2.5. Generation of cardiomyocytes from iPSC  
 
Due to their ability to give rise to any cell typo of the body, iPSCs have been demonstrated 
to be able to spontaneously differentiate into contracting cardiomyocytes (CMs) (Xu, Police 
et al. 2002; He, Ma et al. 2003). However, the efficiency of this spontaneous differentiation 
process is very low, and represented for a while a limitation to their massive use.  Over the 
past 10 years, thanks to the gained knowledge on cardiac development, several advances 
have been made that improved the efficiency and reproducibility of the cardiac 
differentiation protocols (Laflamme, Chen et al. 2007; Yang, Zhang et al. 2008).  
Cardiac differentiation methods can be classified into three categories:  
1) co-culture with mouse visceral endoderm-like (END-2) stromal cell; 
2) Embryoid body (EB)-based differentiation; 
3) Monolayer methods. 
The co-culture method was firstly used to demonstrate the differentiation of CMs from ES 
cells, by co-culturing them with END-2 cells (Mummery, Ward-van Oostwaard et al. 2003). 
However this method was limited by a low CMs yield (usually from 10% to 1%) and their 
immature phenotype (Passier, Oostwaard et al. 2005; Fujiwara, Yan et al. 2011).  
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Most of the available methods for differentiating CMs from iPSCs are instead based on EB 
formation. EBs are 3D spherical aggregates that form from pluripotent cells when cultured 
into low-adhesion plates. They mimic embryonic development and can give rise to various 
cell types, including CMs in a range that varies from 5% to 70% (Laflamme, Chen et al. 
2007), depending on the experimental settings. Yield of CMs obtained from spontaneous EB 
differentiation is extremely low, so that administration of chemicals factors and physical 
cues, acting on signalling pathways that are key in driving cardiac development, have been 
introduced to improve the differentiation efficiency. The “hanging-drop” (Yoon, Yoo et al. 
2006) and “spin EBs” (Ng, Davis et al. 2005) are examples of EB-based methods, but still 
with limited efficiency; use of growth factors as Activin A, BMP4, bFGF, WNT-3A, VEGF 
or DKK1 has demonstrated to enhance efficiency and are included in some of the currently 
used protocols (Yang, Zhang et al. 2008).  
More recently, methods that rely on iPSCs differentiation as a monolayer of cells, called 
here “monolayer methods” have prevailed on the other approaches, probably because of their 
ease to handle and the extremely high differentiation efficiency. These methods are based 
on the administration of growth factors and small molecules to iPSCs cultured in monolayer 
conditions; these factors drive differentiation more specifically and increase yield and purity 
of generated CMs. In 2007, the sequential treatments with Activin A and BMP4 was firstly 
applied to ES cells (H7 line) and reported to give rise to >30% contracting CMs at the 12th 
day of the differentiation process (Laflamme, Chen et al. 2007). This differentiation 
efficiency was higher than the one reported using EBs methods at that time.  
In 2010, the formulation of a protocol based the modulation of the WNT/β-catenin signalling 
pathway, which is key in driving early cardiac development, led to a significant improve in 
the field, generating up to 75-90% of highly pure CMs (Paige, Osugi et al. 2010; Zhang, 
Klos et al. 2012; Lian, Zhang et al. 2013). 
In the last few years, the studies on the field have continued to explore strategies to enhance 
quality and purity of the CMs differentiated from iPSC. Tohyama S. and colleagues 
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proposed a protocol to purify CMs over the other contaminant cells, which takes advantage 
of the specific metabolic properties of cardiac cells (oxidative vs glycolytic), demonstrating 
that use of lactate instead of glucose as a nutrient was sufficient to obtain 99% CMs pure 
population (Tohyama, Hattori et al. 2013). Furthermore, a recent study identified a specific 
population of cardiovascular progenitors (CVPCs), which can be obtained in vitro from 
iPSCs, cultured and expanded up to 15 passages and subsequently differentiated in CMs 
(Cao, Liang et al. 2013; Takeda, Kanki et al. 2018). The above described “monolayer 
methods” are summarized in the Figure 9. 
Although functional and structural properties of iPSC-CMs improved over time, these cells 
are still immature if compared with adult CMs (Lieu, Fu et al. 2013). Many attempts have 
been made and are still under investigation to improve maturity of CMs differentiated from 
iPSCs. One possibility is to keep cells in culture for prolonged time (Otsuji, Minami et al. 
2010) or to apply electromechanical stimulations (Nunes, Miklas et al. 2013; Mihic, Li et al. 
2014). Besides the improvements obtained with these approaches, iPSC-CMs still retain 
characteristics which are more similar to foetal than adult CMs (Robertson, Tran et al. 2013). 
Thus, the future directions of the research in the field will move not only to further improve 
the differentiation efficiency but also to develop protocols able to generate more mature 





Figure 9. Schematic representation of differentiation protocols based on “monolayer methods”. CIM: 
CVPCs induction medium; Y: Y27632, Rho-associated coiled coil kinase (ROCK) inhibitor; CDM1/ 2: cardiac 
differentiation medium 1/ 2.  
 
 
Furthermore, it is worth discussing that the differentiation protocols described above give 
rise to a mixed population of cardiac cells, including atrial, ventricular and pacemaker-like 
CMs subtypes.  
Very recently, few studies described new differentiation strategies to promote the generation 
of the specific CMs’ subtypes (Lee, Protze et al. 2017; Cyganek, Tiburcy et al. 2018); this 
possibility represent an important achievement in the field, since it allows modelling of 
cardiac diseases which preferentially affect one cell type, such as atrial fibrillation, 
ventricular tachycardia and cardiomyopathy, and the test of specific therapeutic option in 
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the proper cell type. These protocols are based on induction of specific mesodermal 
progenitor populations, from which atrial and ventricular CMs derive (Lee, Protze et al. 
2017). Results from these studies also provide the access to cells at early stages of cardiac 
development that can be used as platform to study congenital cardiac diseases that are due 
to defects occurring during cardiac development.  
  
 
6.2.6. Basics on cardiomyocytes’ functioning 
 
Mouse and human hearts exhibit different electrophysiological properties. For example, QT 
interval of the ECG profile is five times longer in humans than in mice; these also displayed 
differences in the shape and duration of the action potential (AP), with cardiac AP in mice 
being shorter than that in humans and lacking a clear phase 2 (or plateau) (Davis, van den 
Berg et al. 2011). 
Unlike skeletal muscle APs, which are generated by nervous system activity, the APs in the 
heart are due to events provoked by specialized cardiac tissues areas: the sinus nodes (SN). 
Located between the superior vena cava and the right atrium (RA), nodes are able to initiate 
the impulse propagation that rapidly travels across the myocardium, passing from a cell to 
the adjacent one through gap junctions, which electrically connect myocardial cells. The AP 
travels throughout the whole heart, causing a propagated electrical wave (Feher 2012). The 
AP occurs when the cellular membrane depolarizes (inward currents) and then rapidly 
repolarizes (outward currents), moving back to the resting state (Carmeliet and Vereecke 
2002). The inward currents are mostly generated by voltage-gated Na+ and Ca2+ channels 
(Nav and Cav respectively), while K+ channels are responsible of the outward currents. AP 
profiles vary between different areas of the heart but can be essentially divided into 5 phases, 
summarized below and graphically represented in the Figure 10: 
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- Phase 0: the initial phase of depolarization of the membrane, which quickly brings the 
negatively charged membrane potential (about -80 mV) to a positive value. Na+ rapidly gets 
through voltage-gated sodium channels, allowing cell depolarization. 
- Phase 1: Na+ channels close and repolarization of cell membrane starts. This is mediated 
by K+ channels. At the end of this phase, Ca2+ channels slowly start opening. 
- Phase 2 (or Plateau): the membrane potential is firstly closed to 0 mV and then becomes 
more negative. Plateau is the result of the combination between Ca2+ influx and K+ efflux 
due to a decrease in K+ cell permeability and an increase in Ca2+ permeability.  
- Phase 3: the complete closure of Ca2+ channels and the increased K+ permeability mark the 
end of Plateau phase. K+ influx rapidly restores membrane potential. 
- Phase 4 (or Resting membrane potential): the stable resting potential of myocardial cells 




Figure 10. Atrial (grey line), ventricular (blue line) and sinus node (pink) AP profiles, recorded in human 
and mouse CMs. The different five phases of AP are numbered from 0 to 4, in purple. 
 
 
Although the upstroke due to sodium influx (Na+) is quite similar in mice and humans, 
several differences exist between the two species on regard of the K+ currents. In fact, 
 50 
transient outward potassium current (Ito) is the major outward current in mouse, while slow 
(IKS) and rapid (IKR) delayed rectifier potassium currents, are predominantly present in 
humans. Moreover, IK slow1, IK slow2 and steady-state non-inactivating K+ current (ISS), are 
involved in repolarization phase only in mouse CMs and completely absent in human cells 
(Davis, van den Berg et al. 2011).  
 
6.2.7. iPSCs applications 
 
Being derived from donor/patient-specific cells, iPSCs are a useful tool for a wide variety of 
applications in biomedical research as diseases modelling and drug screening (Fig. 11); at 
the same time, use of these cells overcome the ethical issues associated with the manipulation 
of human embryos and embryonic stem cells. Furthermore, iPSC technology also represents 
a potential source of autologous cells for transplantation (Scheiner, Talib et al. 2014; Singh, 
Kalsan et al. 2015).  
 
 
Figure 11. Schematic representation of iPSCs applications in biomedical research. 
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Their ES-like features, as unlimited proliferation, self-renewal and wide differentiation 
potential, allow the employment of iPSCs in tissue damage repair, in vitro modelling of 
diseases and as a platform for drug-testing. In the past years, several models of iPSCs have 
been generated to recapitulate different diseases in patient-specific relevant cell types, such 
as neurons for several neurological disorders, skeletal muscle and cardiomyocytes for 
dystrophies, arrhythmic disorders and cardiomyopathies, including those related to 
laminopathies (Park, Zhao et al. 2008; Moretti, Bellin et al. 2010; An, Zhang et al. 2012; 
Sun, Yazawa et al. 2012; Priori, Napolitano et al. 2013; Drawnel, Boccardo et al. 2014; Li, 
Fujimoto et al. 2015; Lodola, Morone et al. 2016; De Santis, Santini et al. 2017; Crasto and 
Di Pasquale 2018; Long, Li et al. 2018). 
Furthermore, improvements in genome-editing technologies (Malik and Rao 2013; 
Hockemeyer and Jaenisch 2016) have been the key to overcome the limits of iPSC-based 
disease modelling and to allow the establishment of a causal link between a genetic mutation 
and the “clinical” phenotype of the iPSC-derived cells. On regard of their use in the clinic, 
although still at very early stage, some clinical trials using ESC-derived cells have been 
approved by the Food and Drug administration (FDA) (Goldring, Duffy et al. 2011), paving 
the way for the future clinical application of iPSCs. Very recently few studies reported 
transplantation of cells derived from patient-specific iPSC for treatment of macular 





6.2.8. iPSC-based models of LMNA-CMP 
  
At the moment, only three studies have been reported that employed iPSC-CMs to model 
LMNA-CMP; those are mostly derived from patients carrying nonsense mutations (R225X, 
GCCA insertion, Q354X and T518 frameshift) and have been shown to recapitulate some of 
the morphological and functional defects typical of laminopathy.    
In addition to the well-known morphological defects of the nucleus caused by LMNA 
mutations, increased susceptibility to electrical and physical stresses was reported in LMNA-
CMs, an effect that Siu and colleagues reported as mediated by alteration of ERK1/2 
signalling pathway (Siu, Lee et al. 2012). Accordingly, abnormalities of ERK1/2 pathway 
were also described in iPSC-derived CMs carrying the p.R190W LMNA mutation in 
association with a-sarcomeric actinin disorganization (Chatzifrangkeskou, Yadin et al. 
2018).  
Remarkably, a recent study reported a beneficial effect of ataluren (PTC124), small molecule 
has been approved by the FDA for treatment of genetic diseases due to nonsense mutations, 
on the typical cellular phenotypes of LMNA-CMs and excitation-contraction coupling, 
setting the ground for a wider application of these models for pharmacological testing for 
laminopathies’ treatment. 
However, studies conducted so far were mostly phenomenological, while those focused on 
the molecular mechanisms underlying LMNA mutations in cardiac cells and the epigenetic 
role of LaminA/C in this context are almost absent. 
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7. AIMS AND RATIONALE 
 
LaminsA/C are ubiquitous proteins and, together with Lamins B, constitute the main 
components of nuclear lamina which is critical for the maintenance of the shape and the 
mechanical stability of the nucleus; they also have key roles in other cellular processes, as 
transcriptional regulation and chromatin organization (Worman 2012). 
Mutations in their encoding gene, LMNA, lead to a heterogeneous spectrum of human 
diseases collectively called laminopathies; based on their clinical manifestations, LMNA-
related diseases can be classified into those that affect the striated muscle, the adipose tissue 
and the peripheral nerves or cause systemic diseases, that interest multiple organs and are 
mainly associated with accelerated ageing (progeria) (Muchir, Pavlidis et al. 2007). Cardiac 
involvement is very common in laminopathies and mainly manifests with dilated 
cardiomyopathy (DCM), usually associated with various conduction system diseases 
(CSDs). 
Dilated cardiomyopathy (DCM) is a form of heart disease, associated with systolic 
dysfunction and contractile defects; when DCM is due to LMNA mutations, these clinical 
signs are typically anticipated by CSDs.  
How different mutations in LaminA/C gene can cause such a broad spectrum of diseases 
still remains largely undetermined. With respect of the cardiac pathology, the molecular 
mechanisms underlying the onset and progression of the LMNA-dependent cardiomyopathy 
(CMP) as well as the role played by the nuclear envelope on its pathogenesis are still not 
completely understood. It is therefore crucial to better define how lamins work within the 
cardiomyocyte (CM) and how mutations impact on their functionality. Studies on Lmna 
knock-out mice and transgenic models carrying specific Lmna mutations have given an 
important contribution to shed light on the pathogenetic role of Lamin A/C. However, 
despite the gained knowledge, human studies so far have mainly focused on fibroblasts, 
adipose and muscular cells, while the functional and molecular effects of defective 
 56 
LaminA/C in the human CMs as well as their role in the pathogenesis of the related CMP 
remain poorly understood. Furthermore, several important differences exist between mouse 
and human heart physiology, such as electrical properties, ion channel distribution, and heart 
rate, thus the use of mouse models may fail in reproducing some of the phenotypes as in the 
patients. Use of induced pluripotent stem cells (iPSCs) can overcome those limitations, 
allowing the generation of either patient-specific or isogenic cells of any type, including 
CMs, in which mechanisms of human diseases may be investigated (Takahashi, Tanabe et 
al. 2007; Yu, Vodyanik et al. 2007; Park, Zhao et al. 2008; Di Pasquale, Lodola et al. 2013; 
Lodola, Morone et al. 2016). 
In this study we employed iPSC technology to dissect cellular and molecular mechanisms 
of cardiomyopathy due to LaminA/C mutations. The expected outcome of the proposed 
study is to gain knowledge on the biological functions of LaminA/C in the onset and 
progression of LMNA-dependent CMP (LMNA-CMP) and to dissect the molecular and 
functional mechanisms responsible for the disease phenotype. The specific aims of this 
Thesis are the followings: 
1) To generate iPSC-based models of LMNA-CMP, either from patients or through gene 
editing, carrying K219T and R190W- LMNA mutations, for investigating their role in the 
pathophysiological context of the disease. 
 
2) To determine the pathophysiological traits of LMNA-CMP in CMs derived from 
K219T and R190W-LMNA-iPSC lines. Study of CM phenotypes at the functional and 
molecular level through the combination of gene expression, electrophysiological, 
biomechanical and imaging techniques. Furthermore, gene correction studies, using 
CRISPR/Cas9 approach, will provide the causal link to the disease phenotype. 
 
3) To define the role of LaminA/C and its mutation in transcriptional regulation. A 
special emphasis is given to the role of LaminA/C and the lamina-associated domains 
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(LADs) in structural organization and epigenetic regulation of the chromatin in the CMs. 
While it is generally accepted that the nuclear lamina functions to maintain the shape of the 
nucleus, it has also been demonstrated to play a role in the regulation of gene expression, by 
interacting with transcription factors and chromatin regulators.  
 
4) To validate the use of the generated iPSC-derived models of LMNA-CMs as a 
platform for drug testing. We will perform a series of proof-of-concept experiments to test 
the effect of a small molecule (Remodelin), recently described to improve morphological 
traits of laminopathic cells, assessing its therapeutic potential on identified functional 
outcomes. Results from these experiments will provide us with evidence whether the 























8.1. iPSCs generation 
8.1.1. Cell Reprogramming using STEMCCA lentiviral vector 
 
Reprogramming of K219T LMNA fibroblasts was achieved by transduction of the four 
“Yamanaka” factors (Oct4, Sox2, Klf4 and c-Myc) using the STEMCCA lentiviral vector 
(Sommer, Stadtfeld et al. 2009), kindly provided by Dr. Mostoslavsky (Boston University 
School of Medicine, MA, USA). In brief, 1x 105 fibroblasts isolated from skin biopsies of 3 
members of a family carrying the p.K219T Lamin A/C mutation were infected with 
STEMCCA lentiviral vector, for generated iPSC lines (referred as K219T#1, K219T#2 and 
K219T#3). iPSCs were also generated from two healthy wild-type family members and used 
as controls 
 
8.1.2. Cell reprogramming using Sendai virus  
 
An additional case carrying the p.R190W Lamin A/C mutation was also enrolled in the study 
and iPSCs were generated from peripheral blood mononuclear cells (PBMNCs) using a 
commercially available kit, based on Sendai virus (CytoTune™-iPS 2.0 Sendai 





8.1.3. iPSC lines characterization and maintenance 
 
iPSCs characterization was performed as previously described by us (Di Pasquale, Lodola 
et al. 2013; Lodola, Morone et al. 2016) and included: analyses of expression of pluripotency 
markers (OCT4, REX1, DNMT3B, TRA1-60, SSEA4) either by real time PCR, FACS 
analysis or immunofluorescence, assessment of alkaline phosphatase activity, embryoid 
bodies and teratoma formation assays to assess the ability of reprogrammed cells to 
differentiate into derivatives of the three germ layers, respectively in vitro and in vivo. 
Analysis of the karyotype was also carried out by standard procedures (Paulis, Castelli et al. 
2015). Two clones per patient were used for the experiments. Cells were maintained under 
5% CO2 in Essential 8 medium on Vitronectin (both from ThermoFisher Scientific) and 
passaged 1:5 when 90% confluence was reached (approximately 4-5 days) using 0.5mM 
EDTA after pre-treatment with 10 µM Rho-associated protein kinase inhibitor (Rocki from 
Selleck Chemicals). 
 
8.1.4. Generation of gene-corrected isogenic lines  
 
Gene correction strategy has been developed in the laboratory of Prof. Charles E Murry, at 
the University of Washington (Seattle – USA) and generation of the isogenic lines performed 
in both laboratories. 
In detail, a suitable endogenous “TTAA” site was identified in the third intron of LMNA 
gene (about 130 bp from mutations sites), as close as possible to both mutations. Then, we 
designed a single guide RNA (sgRNA) spanning the TTAA site, so that only the wild-type 
sequence could be cut by CRISPR/Cas9. This strategy allowed us to avoid inserting any 
additional mutation into the targeting vector homology arms (such as those classically used 
to disrupt the PAM site). The sgRNA was designed using mit.crispr.edu and had a score of 
80%, indicating a very high in-silico predicted specificity (sequence without PAM site: 5’-
CTACCAGCCCCACTTTAACC-’3). To further decrease the risk of CRISPR/Cas9 off-
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target activity, we adopted the enhanced specificity SpCas9 (eSpCas9) developed by Dr. 
Feng Zhang and colleagues (Slaymaker, Gao et al. 2016). The sgRNA was cloned into the 
eSpCas9 plasmid (Addgene #71784) using a standard method, based on restriction digestion 
with BbsI followed by ligation of a double-stranded oligo (Ran, Hsu et al. 2013). The 
resulting plasmid was named eSpCas9_LMNA. Sequence was confirmed by Sanger 
sequencing, and the sgRNA was validated to have a high on-target activity as measured by 
T7E1 assay in HEK293 cells. The LMNA targeting vector was made starting from the MV-
PGK-Puro-TK_SGK-005 plasmid (Transposagen), which contains a piggyBac transposon 
encoding a PGK-EM7 promoter- driven a dual positive/negative selection cassette 
(puromycin N-acetyltransferase, ensuring resistance to puromycin, and truncated thymidine 
kinase, conferring sensitivity to ganciclovir or its analogue fialuridine). First, the piggyBac 
cassette was excised using NsiI and BsiWI and isolated. Then, a backbone with ends suitable 
for the subsequent overlap-based assembly was obtained from this same plasmid after 
removal of the piggyBac cassette using NotI and AscI. Finally, these two fragments were re-
assembled together with two PCR products representing the 5’ and 3’ homology arms to the 
LMNA gene. The two homology arms were approximately 1 Kb long, and were amplified 












3’ (for the 3’ homology arm). The four-way assembly reaction was performed using 
NEBuilder HiFi DNA Assembly Kit (New England Biolabs) according to the 
manufacturer’s instructions, and the resulting targeting plasmid was named 
pbLMNA_K219K. Sanger sequencing confirmed that the 3’ homology arm contained the 
wild-type K219K allele, while the remaining genomic sequence of both homology arms was 
identical to that of line LMNA #1_2 as no SNPs were identified. The cloning strategy was 
designed so that during PCR the “TTAA” site was inserted both at the end of the 5’ 
homology arm and at the start of the 3’ homology arm, ensuring that the piggyBac cassette 
contained within could be excised using transposase while leaving behind a single “TTAA” 
matching the original genomic sequence. For the first gene targeting step, 150,000 hiPSCs 
(line LMNA #1_2) were seeded in each well of 6-well plate and immediately transfected 
using GeneJuice (Millipore) according to the manufacturer’s instructions. Briefly, for each 
well 3 µl of GeneJuice was mixed with 100 µl of Opti-MEM (ThermoFisher Scientific) and 
incubated for 5 min at room temperature. 1 µg of DNA was added to the transfection solution 
(equally divided between eSpCas9 LMNA and pbLMNA_K219K), which was further 
incubated for 15 min at room temperature and finally added to the cell suspension. After 16 
h from transfection, cells were washed with DPBS and cultured for another 3 days in 
Essential 8 medium. Media without penicillin/streptomycin was used from two days before 
transfections up to this point, and 10 µM Y-27362 (ROCK inhibitor; SelleckChem) was 
added during plating and left until the subsequent day to increase cell survival. Gene targeted 
cells were selected by adding 1 µg/ml puromycin to the media for 4 days; the dose was then 
reduced to 0.5 µg/ml. 10 µM Y-27362 was added for the first 48 h of selection. Puromycin 
was then maintained at all times until the second gene targeting step to prevent silencing of 
the piggyBack transgene. After approximately 10 days from the transfection, 5-10 individual 
and well-separated colonies could be identified in each well of the 6-well plate, indicating 
that they likely arose from clonal expansion of a single gene-edited hiPSC. Colonies were 
manually picked following gentle treatment with EDTA to facilitate their detachment from 
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the matrix, and individually expanded as individual lines. Clones were screened by genomic 
PCR using LongAmp Taq Polymerase (New England Biolabs) according to manufacturer’s 
instructions, except that all reactions were performed using an annealing temperature of 
63°C and an extension time of 2 min. The primer sequences are reported in Table 5. 
Junctional PCRs for both the 5’ and 3’ integration site (5’- and 3’-INT) were used to confirm 
site-specific integration, while locus PCRs were used to monitor the presence of residual 
wild-type alleles. This step allowed us to discriminate homozygous clones from 
heterozygous ones or mixed cell populations. Finally, PCRs of the targeting vector backbone 
(5’- and 3’-BB) were performed to exclude random integration of the plasmid in the genome. 
Homozygous clones with only on-target integration events were selected (3 out of the 12 
lines screened). These positive clones were further characterized by Sanger sequencing of 
the 5’- and 3’-INT PCR product to confirm the presence of the wild-type K219K allele in 
homozygosity (2 out of 3 lines) and exclude other unwanted mutations elsewhere in the locus 
(absent in all lines). One clone was karyotyped by standard G-banding, which confirmed its 
genetic stability, and therefore selected for the second gene targeting step. This clone was 
named K219K-PB_cl14. To remove the piggyback cassette and restore the LMNA locus to 
its original form, K219K-PB_cl14 hiPSCs were transfected using GeneJuice (Millipore) as 
described above using 1 µg of excision-only piggyBac transposase expression vector (PBx; 
Transposagen). Puromycin was removed from the media the day before transfection, and 
subsequently omitted. After 3 days from the transfection, the population was passaged as 
single cells, and 10,000 cells seeded per 10 cm dish in the presence of 10 µM Y-27362. On 
the next day, 400 nM fialuridine was added for negatively select the cells still carrying the 
piggyBac cassette. 10 µM Y-27362 was added for the subsequent 48 h. Selection was 
maintained for 7 days; at that point 10-50 individual and well-separated colonies could be 
identified in each 10 cm dish. Individual colonies were isolated, clonally expanded and 
screened by genomic PCR as described above to identify those with homozygous 
reconstitution of the wild-type allele (3 out of 15 screened lines). These were further 
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characterized by direct sequencing to ensure that the sequence surrounding the “TTAA” site 
was faithfully reconstituted upon piggyBac excision. The three clones were karyotyped by 
standard G-banding, which confirmed their genetic stability. Subsequent functional 

















































































































































8.2. Cardiac differentiation 
 
iPSCs were differentiated into iPSC-CMs using a monolayer differentiation protocol 
(Nakahama and Di Pasquale 2016) and were maintained in a 5% CO2/air environment. In 
brief, iPSC colonies were dissociated with Accutase (Gibco-Life Technologies) and plated 
at a density of 0.25-0.5 x 105/cm2 in 12-well plates coated with Growth Factor Reduced 
(GFR) Matrigel (BD Bioscience) in Essential 8 medium containing 10µM Y-27362 (Selleck 
Chemicals). Cells were cultured until they reached 85-100% confluence (approximately 4 
days) and then treated for 24 hours with 10-12µM CHIR99021 (Selleck Chemicals) in RPMI 
supplemented with B27 without insulin (the day of the treatment is referred to as day 0). On 
day 3, cells were treated with 5µM IWR-1 (Sigma Aldrich) for 48 hours. Medium was 
replaced on days 5 and 7 with RPMI+B27 without insulin; from day 10, RPMI supplemented 
with B27 and insulin was used and changed every other day. Cells were used for the 
experiments 20-25 days after the start of spontaneous contractions. Data presented are 
average of values obtained in CMs differentiated from two iPSCs lines per subject. 
 
8.2.1. Remodelin treatment 
 
iPSC-CMs were treated with the NAT10 inhibitor, Remodelin (cyclopentylidene-[4-(4-
cyanophenyl)thiazol-2-yl)hydrazine) at final concentration of 5µM for 5 days (Larrieu, 
Britton et al. 2014), starting from day 20 after first contractions; medium supplemented with 
the small molecular was replaced every 2 days. Cells were harvest at day 6 after treatment 





8.2.2. FACS analysis 
 
iPSCs differentiation efficiency was evaluated by FACS through the assessment of 
expression of the cardiac-specific marker α-sarcomeric actinin as previously described 
(Lodola, Morone et al. 2016). In brief, CMs were enzymatically dissociated into single cells, 
fixed in 1% paraformaldehyde and permeabilized; staining and detection were then 
performed using mouse monoclonal α-sarcomeric actinin antibody (1:400 from Abcam, 
Cambridge, UK) and goat anti-mouse Alexa-647-conjugated antibody (1:500 from 
Molecular Probes, Thermo Scientific), respectively. Dead cells were quantified and 
excluded from the analysis using the LIVE/DEAD fixable aqua stain kit (Molecular Probes, 
Thermo Fisher Scientific). Cell acquisition was performed on a FACS LSRFortessa flow 
cytometer (BD Bioscience, San Jose, CA, USA) and data analysed using DIVA software 






8.3. Electrophysiological Analysis 
8.3.1. Patch-clamp recordings  
 
Electrophysiological recordings were performed using a Multiclamp 700B patch-clamp 
amplifier (Molecular Devices) controlled by pClamp 10.3 software (Molecular Devices). 
Low-density cell cultures grown on glass coverslips (VWR international) were transferred 
2-3 days after cell seeding to a custom-made experimental chamber that was fixed to the 
stage of an inverted microscope (Nikon eclipse, Ti/U) and superfused at 1.5 mL/min. Single 
human iPSC-derived cardiomyocytes (iPSC-CMs), identified on the basis of their typical 
morphology, were current/voltage-clamped in the whole-cell configuration of the ruptured 
patch-clamp technique. Data were collected from a minimum of three independent 
differentiations per line. Na+ current (INa) and action potential (AP) signals were low-pass 
filtered at 10 kHz, digitized at 20 and 50 kHz, respectively, and stored for offline analysis 
whereupon the latter was performed using dedicated software (pClamp 10.6 and Clampfit 
10.6; Molecular Devices). Patch pipettes were pulled from borosilicate glass capillaries 
(Intrafil-10, INTRACEL LTD) with a laser-based micropipette puller (P-2000; Sutter 
Instrument) and resistances ranging from 1 to 3 MΩ. After seal formation (2-10 GΩ), 
rupturing of the patch, and before INa measurement, adequate voltage control was achieved 
with membrane capacitance (Cm) and series resistance (Rs: 3–8 MΩ) compensation above 
80% (estimated voltage error <5 mV in all cases), and by maintaining a fraction of channels 
in their inactivated state by using a holding potential of -90mV. Cm was determined by 
dividing the decay time constant of the whole-cell capacitance transient in response to 
hyperpolarizing steps from -50 mV, by the Rs. Statistical comparisons were made using 
Student’s t-test for unpaired samples. Differences with at least p<0.05 were considered 
significant. 
Patch clamp recording were performed by the Electrophysiology Unit of the Institute. 
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8.3.2. Action potential properties measurements  
 
AP characteristics were assessed at 36°C using Hanks’ balanced salt solution (HBSS, Sigma) 
containing: 137 mmol/L NaCl, 5.4 mmol/L KCl, 1.3 mmol/L CaCl2, 1.2 mmol/L MgSO4, 4 
mmol/L NaHCO3, 0.5 mmol/L KH2PO4, 0.3 mmol/L NaH2PO4, 5.5 mmol/L D-glucose and 
10 mmol/L HEPES (pH 7.40 with KOH). The pipette filling solution contained: K-aspartate 
120mmol/L, NaCl 10 mmol/L, MgATP 3 mmol/L, CaCl2 1 mmol/L, EGTA 10 mmol/L, 
HEPES 5 mmol/L (pH 7.2 with KOH). Liquid junction potential corrections (12.4 mV as 
calculated by pCLAMP software; Axon Instruments) were applied after experiments during 
offline analysis. AP measurement experiments were conducted on spontaneously active 
iPSC-CMs. Maximal upstroke velocity (dV/dtmax), peak voltage (Overshoot), action 
potential amplitude (APA), action potential duration at 90% of repolarization (APD90), and 
maximal diastolic potential (MDP) were analysed. APs were recorded from cells able to 
generate spontaneous APs, averaging the 2 last sequential APs obtained from 10 sec current-
clamp recordings.  
 
8.3.3. INa measurements  
 
Whole cell INa recordings were conducted at room temperature in an extracellular solution 
containing: 70 mmol/L NaCl, 1.8 mmol/L CaCl2, 90 mmol/L CsCl, 1.2 mmol/L MgCl2, 10 
mmol/L glucose, 10 mmol/L HEPES, and 0.001 mmol/L Nifedipine (pH 7.4 with CsOH) 
and pipette solution filled with: 130 mmol/L CsCl, 10 mmol/L NaCl, 1 mmol/L CaCl2, 10 
mmol/L EGTA, 5 mmol/L HEPES, 3 mmol/L Mg-ATP (pH 7.2 with CsOH). Potentials were 
corrected for the estimated change in liquid junction potential of 6 mV before experiments. 
Peak INa densities and the voltage-dependence of activation were characterized as follows: 
single cells were held at -90mV and 100 msec voltage steps were applied from -90 to +80mV 
in 5 mV increments with a cycle time between voltage steps of 3 sec. Voltage-dependence 
of inactivation was assessed by holding cells at various potentials from -130 to 15 mV 
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followed by a 50 msec test pulse to -20mV to elicit INa (holding potential of -90 mV). To 
take into account the variations in cell size, current amplitude was normalized to Cm and 
expressed as current density (pA/pF). Activation and inactivation curves were described by 
fitting experimental points with the Boltzmann equation to estimate the voltages of half-
maximal activation and inactivation (V1/2) and each slope-1 factor (k). 
 
8.3.4. Optical measurements of impulse propagation 
 
Action potential propagation were assessed optically using 80µm width strand preparations 
loaded with the voltage sensitive dye di-8-ANEPPS (135 µmol/L for 4 minutes; Life 
Technology) as described previously (Miragoli, Gaudesius et al. 2006). Loaded preparations 
were mounted in a temperature-controlled chamber (University of Bern, CH) placed on the 
stage of an inverted microscope (Nikon Ti/U) and were superfused at 36°C with HBSS 
containing 1% FBS. Strands were recorded as spontaneously contracting or stimulated with 
a bipolar electrode placed ≥ 1 mm from the measurement site in order to permit action 
potential propagation to reach steady-state conditions at the recording site. Strands were 
stimulated for the entire duration of recording (4 seconds, 5 stimulus) by a stimulator (TTi 
110, Harward Apparatus) at a basic cycle length of 500 ms or 1000 ms. Recordings were 
made at 10x magnification (S-Fluo 10x, 0.5 N.A., Nikon) allowing to monitor the activity 
of two strands in one field of view. Impulse propagation was acquired by a fast-resolution 
camera at 1-5 kHz temporal resolution (Ultima L, Scimedia, USA). The amplitude of 
optically recorded action potential upstrokes was scaled to 10% (dF/F). Conduction 
velocities were computed by calculating the activation times for a given strands and divided 
by the covered space of the propagation with a dedicated software (BrainVision AN 1812).  
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8.3.5. Evaluation of contraction force through IonOptix 
 
iPSC-CMs were plated on 22mm glass and loaded with 5µM Fura-2 acetoxymethyl ester, 
Fura-2 AM (Molecular Probes Inc, Eugene, OR). The chamber was perfused with HBSS 
buffer supplemented with 10 mM Hepes and the temperature was constantly kept at 37°C. 
Electrical pulses were introduced through a field stimulator at the frequency of 0.5, 1 and 2 
Hz. The chosen cell cluster was visualized by the IonOptix imaging software, in the edge 
detection mode. Two markers for the cell edges were positioned manually by the operator. 
The cell shortening and calcium transients were then recorded with the following protocols: 
spontaneous beating (baseline) followed by either electrodes stimulation or ß-adrenergic 
stimulus by isoproterenol (1µM). 
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8.4. Molecular Studies 
 
8.4.1. Gene expression studies 
 
Total RNA was extracted with Trizol Reagent and quantified using Nanodrop (NanoDrop 
2000c Spectrophotometer, Thermo Fisher Scientific). RNA was reverse transcribed with 
SuperScript VILO cDNA Synthesis Kit (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Quantitative reverse transcriptase PCR (qRT-PCR) was 
performed using SYBR Select Master Mix for CFX (Thermo Fisher Scientific) and the 
relative expression calculated as 2-ΔΔCt using the comparative Ct method using 18S or 




















8.4.2. Western Blot 
 
Protein lysates (30µg) from CNTR- and LMNA-CMs were loaded on precast 
polyacrylamide gels (Bolt 4-12% Bis-Tris Plus Gels, Invitrogen) and transferred to 
nitrocellulose membranes. Membranes were blocked with 5% milk in TBS-0.1% Tween for 
1 hour at room temperature and then incubated overnight with primary antibodies (anti-
Nav1.5 1:1000 from Cell Signaling, D9J7S; anti-β-actin 1:2000 from Santa Cruz, sc1615). 
Detection was performed after 1-hour incubation with the appropriate secondary antibody 
(1:2000) using the Millipore Chemiluminescent HRP substrate kit. Quantification of Nav1.5 
level was determined by densitometric analysis relative to β-actin, using Fiji-ImageJ 
software. 
 
8.4.3. Co-immunoprecipitation (Co-IP) experiments 
 
Co-IP was performed as previously described (Cesarini, Mozzetta et al. 2015). In brief, 
nuclear extracts were obtained using PARISTM KIT (Ambion AM1921). 0.5 mg of nuclear 
extracts were immunoprecipitated overnight at +4° with 5 µg of antibodies (Lamin A/C, 
Santa Cruz mAb sc-7292-x; unrelated IgG) in a nuclei lysis buffer (10mM Hepes, pH 7.5, 
1.5mM MgCl2, 150mM KCl, 10% glycerol, 0.2% NP-40, 1mM DTT, and protease 
inhibitors). Eluates were analysed by western blot as described above, using anti-Lamin A/C 
(Santa Cruz mAb sc-7292-x) and anti-EZH2 (ACTIVE MOTIF mAb catalogue #39875, 




iPSC-CMs were dissociated and plated onto glass cover-slips coated with fibronectin and 
laminin. Cells were prepared for staining by fixing in 4% paraformaldehyde; cells were then 
rinsed with PBS-0.1% Tween, blocked with 3% goat serum, and permeabilized with 0.1% 
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Triton X-100 for 1 hour at room temperature. Cells were then incubated overnight at +4°C 
with the primary antibodies: anti-Nav1.5 channel (anti-rabbit from Alomone, #ASC005; 
1:100) and anti-α-sarcomeric actinin (Abcam EA-53 ab9465, 1:100). For the detection, cells 
were washed three times with PBS-0.1% Tween and incubated for 1 hour at room 
temperature with Alexa-Fluor 488- and 555-coniugated secondary antibodies (Molecular 
Probes from Thermo Scientific) raised in the appropriate species for the experiments. Nuclei 
were stained with DAPI. Images were acquired on an Olympus FV1000 confocal laser-
scanning microscope with x60 oil immersion objective and analysed using ImageJ Fiji 
software. For tissue immunofluorescence staining, paraffin-embedded heart sections (3µm 
thick) from three healthy controls (commercially available from Proteogenex) and four 
patients were used. Paraffin was removed from tissue sections with sequential treatment with 
xylene, 100% EtOH, 95% EtOH, and 70% EtOH, and slides subsequently rehydrated with 
ddH2O. Prior to immunostaining, we performed antigen retrieval by leaving sections at 98°C 
for 25 minutes in citrate. Slides were blocked with 3% goat serum and permeabilized with 
0.3% Triton X-100 for 40 minutes at room temperature. Tissue sections were then washed 
three times with PBS-T (Tween 0.05%) for 5 minutes and then incubated overnight at +4°C 
with primary antibodies (anti-rabbit Nav1.5, 1:100, from Alomone, #ASC005; anti-mouse 
α-sarcomeric actinin, 1:100, from Abcam, EA-53 ab9465). After 3 washes with PBS-0.1% 
Tween, slides were incubated with secondary antibodies for 1 hour at room temperature 
(Alexa Fluor 555-coniugated goat anti-rabbit, 1:500; Alexa Fluor 488-coniugated goat anti-
mouse, 1:500, both from Molecular Probes). Nuclei were detected with DAPI. Images were 
acquired at x100 on an Olympus FV-1000 confocal laser-scanning microscope with an oil 




8.4.5. Stimulated emission depletion (STED) microscopy 
 
iPSC-CMs were plated on glass coverslips (18mm, #1.5) and prepared for staining by fixing 
in 2% paraformaldehyde. Cells were then rinsed with PBS-0.1% Tween, blocked with 3% 
goat serum, and permeabilized with 0.1% Triton X-100 for 1 hour at room temperature. Cells 
were then incubated overnight at +4°C with the primary antibodies: anti- Lamin A/C (anti-
mouse, from Santa Cruz 7292-X, 1:250) and anti-Suz12 (anti-rabbit, from Cell Signalling 
#3737, 1:250). After three washes with PBS-0.1% Tween, cell were incubated for 1 hour at 
room temperature with Abberior STAR-RED and STAR 580-conjugated secondary 
antibodies raised in the appropriate species for the experiments. Images were acquired on a 
Leica TCS SP8 STED 3X microscope in “counting mode” with a 100x oil immersion 
objective, using detection-lasers at wavelengths of 634 and 561 nm and 775 depletion-laser, 
with a z-step of 60nm. Colocalization analysis was performed with Imaris software 
(Bitplane). We measured the number of voxels on the 3D reconstructions of Lamin A/C- 
Suz12 colocalization channel. Statistical analysis was performed using an unpaired Mann-
Whitney test with 95% confidence interval. 
 
8.4.5.1. Distance distribution analysis 
 
PRC2-LaminA/C distribution profile was calculated using the “Distance transformation” 
Xtension of Imaris Bitplane11. Spot option was used to count point-like objects in all 
acquired z-stacks. LaminA/C, Suz12 and colocalization channels were re-created using spot 
settings and visualized as “spheres” with an estimated XY diameter of 0.227 µm and a 
threshold quality above 0.800 fluorescent signal for Lamin A/C; and XY diameter of 0.227 
µm and a threshold quality above 0.300 fluorescent signal for Suz12 and colocalization 
channels. The outside “ring of spots” of Lamin A/C was selected and used as the “nucleus 
edge” to calculate Suz12 and colocalization channel distances and distributions within 
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nuclei. Data were further analysed by dividing cell nuclei into three zones of 2.15 µm in 
length from the periphery to the centre. 
 
8.4.6. 3D- DNA immuno-FISH 
 
Immunofluorescence coupled with DNA in situ hybridization on preserved nuclei (3D DNA 
immuno-FISH) was performed on sterilized 18-mm round coverslips in 12-well tissue 
culture dishes. The nuclear lamina was visualized using an anti-Lamin A/C antibody (goat 
IgG, from Santa Cruz Biotechnology, sc-6215 N18). DNA hybridization probe was 
generated by nick translation (Nick translation DNA labelling system - Enzo Life Sciences) 
in the presence of Spectrum Orange dUTP nucleotide (Vysis) of the RP11-356A22 BAC 
(Children’s Hospital, Oakland, CA) containing the sequence of the SCN5A gene. CNTR- 
and LMNA-CMs were fixed in 2% paraformaldehyde on slides. Cells were permeabilized 
and incubated for 30 min in blocking solution (3% normal rabbit serum, 0.4% Triton X-
100). Cells were then incubated with the primary antibody (1:100) overnight at 4°C. After 
overnight incubation, samples were washed three times with PBS-Tween 0.1% and 
incubated with Alexa Fluor 488-coniugated secondary antibodies (Invitrogen, A-11078) 
diluted 1:500 for 1 h at room temperature. After rinsing, the samples were permeabilized 
with ice-cold detergent (0.7% Triton-100/0.1M HCl) and FISH was performed to detect 
SCN5A localization. The labelled probe was resuspended in hybridization buffer (50% 
formamide, 10% dextran sulphate, 1x Denhart’s solution, 0.1% SDS, 40 mM Na2HPO4, pH 
6.8, 2xSSC) containing a 10x excess of human Cot1 DNA (Life Technologies), and 
denatured at 80°C for 10 min. In situ hybridization was performed as previously described, 
with minor modifications (Paulis, Castelli et al. 2015; Paulis, Castelli et al. 2015). In brief, 
slides were denatured in 70% formamide/2xSSC at 78°C for 10 min, and hybridized for 48h 
at 37°C. Stringent washings were done with 50% formamide/2xSSC at 37°C. Slides were 
mounted with Vectashield mounting medium and DAPI, and then scored under an Olympus 
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FV-1000 confocal laser-scanning microscope at x100 with an oil immersion objective, using 
x2 optical zoom with a z-step of 0.3µm between optical slices. Distances between each 
SCN5A locus and the nuclear periphery were measured with Fiji-ImageJ software through a 
3D distance map construction on the DAPI channel. 
 
8.4.7. Chromatin immunoprecipitation (ChIP) 
 
Differentiated iPSC-CMs were fixed in 1% formaldehyde for 10 min and then quenched 
with 0.125M glycine for 5 min. Fixed cells were lysed in IP buffer made from two volumes 
of SDS buffer (100mM NaCl, 50mM Tris-HCl pH 8.1, 5mM EDTA pH 8.0, 0.5% SDS), 
one volume of Triton buffer (100mM NaCl, 100mM Tris-HCl pH 8.1, 5mM EDTA pH 8, 
5% Triton X-100) and protease inhibitors (Roche) for 10 min on ice. Chromatin was 
sonicated with a Bioruptor Diagenode Sonicator and immunoprecipitated overnight on a 
wheel at 4°C with 4µg LaminA/C antibody (anti-LaminA/C (636), from Santa Cruz 
Biotechnology, sc-7292x), 5µg of antibodies against the major histone modifications (anti-
H3K4me3, from Active Motif, 39159; anti-H3K27me3, from Abcam, ab6002; anti-
H3K9me3, from Abcam, ab8898) and anti-Suz12 antibody (Cell Signaling, #3737) at the 
1:100 diluition. The bound complexes were washed with Mixed Micelle buffer (20mM Tris-
HCl pH 8.0, 150mM NaCl, 5mM EDTA pH 8.0, 5% Sucrose, 1% Triton X-100, 0.2% SDS), 
Buffer 500 (50mM Hepes, 0.1% deoxycholic acid, 1% Triton X-100, 500mM NaCl, 1mM 
EDTA pH 8.0), and LiCl buffer (10mM Tris-HCl, pH 8.0, 0.5% deoxycholic acid, 0.5% 
NP40, 250mM LiCl, 1mM EDTA pH 8.0). Cross-linking was reversed by incubation at 65°C 
overnight in elution buffer (100mM NaHCO3, 1%SDS), and DNA was extracted from 
Dynabead Protein G (Life Technologies) using the standard phenol/chloroform protocol and 
then resuspended in 20µl of ddH20. qPCR was performed in triplicate using SYBR Select 
Master Mix for CFX. Ct values were calculated by appropriated software and relative 





Two 10µm sections of formal-fixed and paraffin-embedded (FFEP) heart tissue were used 
as starting material. The procedure was performed as previously described	(Fanelli,	Amatori	
et	al.	2010) with modifications. 
In brief, paraffin was efficiently removed with fresh Histolemon solution (Carlo Erba). 
Subsequently Histolemon was replaced with sequential 1ml washes of 100%, 95%, 70%, 
50%, 20% ethanol and ddH2O. For the chromatin extraction step, sections were resuspended 
in 500 µl of Lysis buffer (10mM Tris-HCl pH 7.4, 150mM NaCl, 3 mM CaCl2, 2 mM MgCl2, 
0.5% Tween 20, 10 µg/ml RNAse A, 0.1 mM PMSF). The lysates were then resuspended in 
200 µl of Digestion Buffer. Samples were sonicated four times with a 3-mm microtip probe 
at 25 W for 30 seconds on ice with a Branson 250. 1 U of micrococcal nuclease (USB, 
#70196Y) was added to every 10µg of preheated chromatin (3 minutes at 37°C) and 
incubated at 37°C for 1 minute. The digestion was stopped by addition of 0.5M EDTA to a 
final concentration of 12.5 µM. The sections were then resuspended in 200 µl of Extraction 
Buffer (10 mM Tris-HCl pH7.4, 150 mM NaCl, 3 mM CaCl2, 2 mM MgCl2, 0.1% SDS, 0.1 
mM PMSF). Samples were sonicated for six times with a 3-mm microtip probe at 30 W for 
20 seconds on ice. After the centrifugation step the supernatant containing purified 
chromatin was collected and stored in a clean 1.5 ml Eppendorf tube. The amount of 
chromatin was checked with Qubit (Thermo Fisher Scientific). For the immunoprecipitation 
step, 3µg of ChIP-grade antibody was added to 1µg of tissue chromatin in 500 µl of 
Incubation Buffer (20mM Tris-HCl pH 7.4, 5mM EDTA, 50mM NaCl, 0.1mM PMSF) and 
incubated in rotation (15 rpm) overnight at +4°C. The bound complexes were washed twice 
with 1 ml of ice-cold Washing Buffer A (20mM Tris-HCl pH 7.4, 5mM EDTA, 50mM 
NaCl) and 8 ml of the same buffer (containing Triton X-100) were added. After the 
centrifugation step, the pellet was washed with 10 ml of ice-cold Washing Buffer B (50 mM 
Tris-HCl pH 7.4, 10mM EDTA, 100mM NaCl) and 10ml of ice-cold Washing Buffer C 
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(50mM Tris-HCl pH 7.4, 10mM EDTA, 150 mM NaCl). The pellet was resuspended in 1 
ml of ice-cold Washing Buffer C (without Triton X-100) and transferred to a clean 1.5 ml 
Eppendorf tube. The bound chromatin was eluted by addition of 300–500 µl 1% SDS in TE. 
0.2 M NaCl was added to all samples (input and bound fractions) and samples incubated at 
65°C overnight to reverse formaldehyde crosslinks. The next day, 10mM EDTA was added 
to all samples to a final concentration with 50mM Tris-HCl pH 6.5, 100 µg/ml Proteinase K 
and incubated at 45°C for 3 hours. The DNA was extracted from protein G-Sepharose (50% 
slurry, Zymed) with phenol-chloroform. qPCR was performed in triplicate using SYBR 
Select Master Mix for CFX. Ct values were calculated by appropriated software and relative 
























8.4.9. Lentiviral-mediated Overexpression 
 
For overexpression experiments, a lentiviral construct encoding C-terminus GFP-tagged 
LaminA/C carrying the K219T mutation (c.A656C) was obtained from Origene in the 
pLenti-EF1alpha-GFP vector (CW104035). We also generated a lentiviral construct 
encoding C-terminus GFP-tagged wild-type LaminA/C by subcloning the WT LMNA gene 
into the same pLenti-EF1alpha-GFP vector backbone. Lentiviral particles were produced in 
HEK293T cells and used to transduce iPSC-derived CMs as previously reported (Di 
Pasquale, Lodola et al. 2013). For LaminA/C overexpression experiments, transduction was 
performed between days 5 and 6 of the differentiation, a stage at which LaminA/C starts to 
be expressed in this system; cells were used for electrophysiology and for gene expression 
studies 20 days after the start of spontaneous beating. For gene expression, cells were sorted 



























Patient-specific iPSC lines were generated from three familial cases, carrying the p.K219T 
LaminA/C (c.A656C) heterozygous mutation (Fig.12), and diagnosed with Dilated 
Cardiomyopathy (DCM) in association with arrhythmogenic events (Roncarati, Viviani 





Figure 12. Family tree. iPSCs lines were generated from patients, carrying the K219T-LMNA mutation (red 














K219T#1 DCM No F 15 Yes 
K219T#2 DCM Yes M 54 Yes 
K219T#3 DCM Yes M 51 Yes 
CNTR#1 healthy No M 29 No 
CNTR#2 healthy No F 32 No 
R190W DCM Yes M    30 Yes 
Table 8. Summary of patients’ information. M: male; F: female. 
 
 
iPSC lines were generated from fibroblasts isolated from patients’ skin biopsies through the 
transduction of the four “Yamanaka” factors (SOX2, OCT-4, KLF-4 and c-MYC) using 
STEMCCA lentiviral vectors, as previously described (Sommer, Stadtfeld et al. 2009). As 
controls, iPSC lines were also obtained from 2 wild type healthy family member.  
An additional case carrying the p.R190W (c.C568T) LMNA heterozygous mutation was also 
enrolled in this study and iPSCs generated from peripheral blood mononuclear cells after 
their activation to T-lymphocytes. 








Figure 13. Genetic analyses of the p.K219T and p.R190W – LMNA mutations. (A) Schematic 
representation of the Lamin A protein structure, showing the localization of the p.K219T  and p.R190W 
mutations. (B) Representative electropherograms from DNA sequencing of exons 3 and 4 of LMNA gene 
showing that the generated K219T LMNA-iPSC lines carried the alanine-to-cytosine transversion at position 
656 (c.656A<C) in heterozygosity in exon 4 as in the patients (the reverse sequence is shown in the figure; the 
T<C mutation is indicated by the arrow) and that R190W LMNA-iPSC lines carried the cytosine to thymine 
transversion at position 568 (c.568C<T) in exon 3. CNTR iPSCs were wild-type. (C) Karyotype analyses 









As following step, a detailed characterization assessing the actual pluripotency of the 
generated lines and their genomic stability was performed (Fig. 14 and Fig. 15). iPSC 
colonies were stained with antibodies against the pluripotency markers OCT4 (green) 
SSEA4 (green) and TRA1-60 (red) (Fig.14-A and Fig.15-A) and tested for the alkaline 
phosphatase (AP) activity (Fig.14-C and Fig.15-C). Furthermore, we evaluated the 
expression of classic embryonic stem (ES) cell marker genes by real time qPCR (Fig.14-B 







Figure 14. Characterization of the pluripotent state of iPSCs generated from patient-derived fibroblast 
with and without LaminA/C p.K219T mutation. (A) Immunofluorescence staining showing the expression 
of OCT4 and of the surface pluripotency markers SSEA4 and TRA1-60 in the generated CNTR- and K219T-
iPSC lines. Nuclei were stained with DAPI. (B) Indicative images of AP activity in CNTR and K219T-LMNA 
iPSC lines. (C) qRT-PCR for OCT4, REX1 and DNMT3B genes, showing the expression of the three markers 
of pluripotency in two lines per subject. Data are relative to parental fibroblasts and were normalized using 
HPRT as housekeeping gene. cDNA from the RUES2 ES cell line was used as a positive control. (D) Teratoma 
formation assay demonstrating the ability of the generated lines to differentiate in vivo into tissues originating 
from ectoderm (neural rosettes, retinal epithelium), mesoderm (cartilage, adipose tissue and muscle), and 





Figure 15. Characterization of R190W-iPSC lines. (A) Flow cytometry analysis of iPSCs to verify the 
expression of pluripotency markers SSEA4 and TRA1-60. (B) qRT-PCR for OCT4, REX1 and DNMT3B genes, 
showing the expression of the three markers of pluripotency in two selected lines. (C) Indicative images of AP 




9.2. Cardiac differentiation and morphological analyses 
 
Generated iPSCs were then differentiated into cardiomyocytes (CMs) for the functional and 
molecular studies. Cardiac differentiation has been achieved using a protocol optimized in 
the laboratory, which is based on the modulation of the WNT signalling pathway in a serum-
free and chemically defined medium (Nakahama and Di Pasquale 2016) and allows the 
obtainment highly enriched iPSC-derived CMs (iPSC-CMs), reaching a differentiation 
efficiency of about 75-90%. The protocol is schematically described in the Fig.16. In brief, 
iPSCs were cultured until they reach 85-100% confluence (approximately 4 days from the 
seeding) and treated for 24 hours with 10-12µM (depending on the specific iPSC clone) 
CHIR99021, an activator of the WNT pathway, in RPMI+B27 supplement in absence of 
insulin. Then, on day 3 cells were treated with 5µM IWR-1 for 48 hours to inhibit the WNT 
signalling. 
From day 10 cells were maintained in RPMI+B27 supplement with insulin and were cultured 
20-30 days after spontaneous contractions start. 
 
 
Figure 16. Cardiac differentiation protocol. The cartoon shows the steps of the differentiation protocol 
employed to obtain cardiomyocytes (CMs) starting from iPSCs.  
 
 
The efficiency of differentiation into CMs was tested by FACS analysis through the 
evaluation of the expression of cardiac-specific marker a-sarcomeric actinin in all the 




Figure 17. Flow cytometry analysis of iPSC-CMs. (A) Left: representative flow cytometry plots of human 
iPSC-CMs. Debris were excluded and cells were selected based on size (upper left panel). After exclusion of 
doublets (upper right panel) and dead cells, single live cells were analysed using a cardiac-specific antibody 
against sarcomeric α-actinin. Scatter plots and gates of a representative experiments in CNTR- and K219T-
LMNA lines are shown in the bottom panels. (B-C) Percentage of sarcomeric α-actinin+ cells and of live cells. 
Histograms depict all clones analysed in duplicate. 
 
 
Following differentiation, we first evaluated the morphological properties of the derived 
CMs. The morphological analyses revealed significant structural differences between CNTR 
and LMNA (mutated) CMs. The a-sarcomeric actinin immunofluorescence staining in 
Figure 21 (A and –B panels) shows a severe sarcomeric disorganization in CMs carrying 
K219T and R190W LaminA/C mutations. Furthermore, patch-clamp recordings in these 
cells revealed an augmented membrane capacity in LMNA mutant CMs, an indication of the 
increased size of the cells (Fig.18-C). From these experiments we can conclude that the 
generated models recapitulate the main morphological phenotypes of patients with DCM, a-
sarcomeric disorganization and dilatation. 
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Figure 18. K219T LMNA-CMs recapitulate typical morphological traits of DCM. (A) Alpha sarcomeric 
actinin staining of CMs differentiated from CNTR, K219T and R190W LMNA-iPSCs revealed sarcomeric 
abnormalities (fragmented and punctuated staining) in those generated from the mutant lines. Nuclei were 
stained with DAPI. (B) Bar graph of the percentages of cells displaying sarcomeric disorganization in CNTR 
K219T and R190W cells. CNTR-CMs, n=83, K219T-CMs, n:126, R190W-CMs, n=97. All value are reported 
as mean ± SD. *p<0.05; ***p<0.0001 (unpaired t-test). (C) Patch-clamp recordings of the membrane capacity 
in CNTR-CMs and K219T-CMs showing a higher mean value in the latter population. CNTR-CMs, n=46, 











9.3. Transcriptional profiling of LMNA-CMs 
 
In order to globally determine which pathways were altered by Lamin A/C mutations, we 
performed a global transcriptional profiling of CNTR and K219T LMNA-CMs by total RNA 
sequencing (Fig.19); the bioinformatics analysis revealed more than 1400 genes 
differentially modulated between the two experimental conditions. Analysis of the molecular 
functions and of the disease pathway by IPA (Ingenuity Pathway Analysis) indicated that 
those mis-regulated genes in LMNA-CMs encode proteins with key functions in cardiac 
conduction, metabolism, and muscle contraction. 
Cardiac conduction abnormalities and contractility defects represent major clinical traits of 
LMNA-CMP. Therefore, based on the evidence from the transcriptome analyses, the 
following studies have been focused on the role of LaminA/C mutations in these two physio-
pathological processes, to determine whether LaminA/C affect those functions through 




Figure 19. Transcriptional profile of LMNA-CMs. (A) Heatmap of the coding mRNA found differentially 
modulated in CNTR and K219T LMNA-CMs; (B) RPKM (Reads Per Kilobase Million) analysis showing 
genes differentially modulated: 970 up-regulated and 512 down-regulated in K219T LMNA-CMs samples 
compared to CNTR. (C) Table summarizing the functional pathways relative to the modulated genes, up-





9.4. Functional studies: 
 
From action potential characteristics to determination of 
conduction properties of LMNA-CMs 
 
In parallel to the definition of the transcriptome of LMNA-CMs, we also performed a 
comprehensive electrophysiological analysis assessing their main action potential (AP) 
properties by conventional whole-cell patch-clamp technique. Results from these 
experiments showed that the functionality of CMs was significantly affected by LMNA 
mutations. As shown in the Figure 23, maximal diastolic potential (MPD), maximal upstroke 
velocity (dV/dtmax) and the related AP properties, such as overshoot and AP amplitude 
(APA), were significant altered in K219T-CMs. In brief, we found MPD value increased in 
K219T-CMs (Fig.20-A), as indication of a more depolarized status compared to control 
samples. Moreover, we observed a significant decrease of dV/dtmax (Fig.20-B left panel), 
indicative of peak sodium current (INa) during the upstroke (Cohen, Bean et al. 1984; 
Berecki, Wilders et al. 2010), and the related AP properties, which in turn are representative 
of cardiomyocyte excitability and proper expression and functionality of Nav1.5. 
Based on both, results on altered cardiac conduction from transcriptional analysis and 
functional studies indicating defects on properties of cardiac excitability, the following 
studies were centred on deepening the mechanisms underlying those functions identified 
altered in LMNA-CMs and the specific role of LaminA/C defects in these processes. 
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Figure 20. Action potential properties of LMNA-CMs. (A) Examples of spontaneous APs recorded in 
CNTR and LMNA-CMs (right panel; scale bar, 1 sec) and dot plot with maximal diastolic potential (MDP) 
data (left panel) recorded from CNTR and K219T-CMs, showing a depolarization of K219T cells. CNTR: 
n=45; K219T=46. (B) Dot plots for the main excitability features measured in spontaneously active iPSC-
CMs: maximal upstroke velocity (dV/dtmax), overshoot and action potential amplitude (APA) are shown. All 
values are reported as mean ± SD. *p<0.05; **p<0.005 (unpaired t-test). Data are relative to CMs differentiated 
from 2 lines from each subjects (2 CNTR and 3 K219T-LMNA). 
 
 
9.4.1. LMNA mutant CMs exhibit reduced sodium current density and 
defects in propagation of the electrical impulse 
 
With the aim to further dissect the functional phenotype of CMs with LMNA 
mutations and to deepen the mechanisms at the basis of the AP abnormalities previously 
found in those cells by patch-clamp, we next investigated the effects of the LMNA mutations 
on INa density in iPSC-derived CMs. Therefore, we measured INa peak density of fast 
voltage-dependent sodium channels (Nav1.5) by whole-cell patch clamp, using specific 
voltage protocols and external ionic solutions and found that the average peak INa density in 
K219T-and R190W-CMs was significantly lower than in CNTR cells (Fig. 21), with a 
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reduction of  >40% at the membrane potential of -30 mV (Fig. 21). No significant differences 
in voltage dependence of activation and inactivation parameters (half-maximal voltage [V1/2] 
and slope factor [k]) were instead detected between wild-type and mutated CMs (Fig. 21-
C). 
Therefore, an impairment of INa was observed in K219T- and R190W-CMs, which is 





Figure 21. Voltage-gated sodium currents in K219T- and R190W-CMs. (A) On the left, representative Na+ 
current (INa) traces recorded in control (top-left), R190W (top-right) and K219T (bottom) –LMNA-CMs (scale 
bar 2ms, 50pA/pF) The right panel shows I-V curves of average peak sodium current density. Results showed 
a significant reduction in R190W and K219T-CMs. (CNTR: n=23; R190W: n=18; K219T: n=22); (B) INa 
density, analysed at -30mV. Data are measured in R190W-CMs (110.93 ± 40.61 pA/pF) and K219T-CMs 
(91.58±30.69 pA/pF) relative to CNTR-CMs (156.12±33.73 pA/pF) and expressed as a percentage. (C) Steady 
state of activation (CNTR: n=23; R190W: n=18; K219T: n=22) and inactivation (CNTR: n=18; R190W: n=14; 
K219T: n=17) curves. Data are relative to iPSC-CMs differentiated from 2 independent lines from two CNTR, 




INa and dV/dtmax are major players in driving the impulse propagation across the 
myocardium; we therefore hypothesized that defects at this level may exert an effect on 
cardiac impulse propagation and measured the propagation velocity of the APs in a confluent 
multi-cellular setting, which is electrically-coupled iPSC-CMs cultured on 80 µm wide 
strands (Fig. 22-A). For the analysis, cells were loaded with the voltage-sensitive dye DI-8-
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ANEPPS and elicited with electrical stimulation at increasing frequencies. Results showed 
that CMs carrying K219T mutation failed to respond to increasing electrical stimulation at 
frequencies of 1Hz and 2Hz (Fig. 22-B). The resulting block (2:1, 3:1 or complete) of the 
impulse propagation is in agreement with the prolonged absolute refractory period secondary 
to the reduced sodium currents. Furthermore, K219T-CMs showed a significant decrease of 
the conduction velocity (CV) (Fig. 22-C), further supporting the notion of an impairment of 




Figure 22. Generation and propagation of optical action potentials in K219T iPSC-CMs. (A) 
Representative images of a monolayer of iPSC-CMs in geometrically-defined strands (80 µm wide, 1-cm long). 
(B) Percentage of propagated APs at 1 and 2 Hz stimulation. (C) The bar graphs represent conduction velocity 
recorded in cell strands consisting of CNTR and K219T-CMs. CNTR: n=47; K219T: n=40. All values are 
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reported as mean ± SD. **p<0.005 (unpaired t-test). Data are relative to CMs differentiated from 2 independent 




9.5. Molecular mechanisms 
of cardiac conduction defects in LMNA-CMs 
 
9.5.1. Reduced sodium currents in K219T-CMs are determined by 
reduced expression of Nav1.5 and its encoding gene SCN5A 
 
To deepen the molecular mechanism underlying the reduced sodium currents density in CMs 
carrying LaminA/C mutations, we first determined whether the cardiac sodium channel 
Nav1.5 was correctly expressed and localized within the CMs by immunofluorescence. 
Surprisingly, we found that the expression of the protein was significantly reduced in CMs 
carrying the K219T-mutation in respect to the control cells (Fig. 23). Western blot analysis 
confirmed these results and showed a reduced expression of Nav1.5 in the mutant cells.  
Next, we investigated whether a diminished transcription of the Nav1.5’s encoding gene, 
SCN5A, may be at the basis of our observations. In fact, among the diverse biological 
functions attributed to LaminA/C, a role in regulating gene expression has been described 
(Lund, Oldenburg et al. 2013; van Steensel and Belmont 2017). Moreover, relatively recent 
studies have indicated a link between LaminA/C defects and altered gene expression in 
different pathological contexts (Lee, Jiang et al. 2016; Lee, Lau et al. 2017).  
Based on these premises, we analysed the relative expression of SCN5A in CNTR and 
LMNA-CMs by qRT-PCR. Results from these experiments are shown in the Figure 24 and 
indicate significantly reduced levels of SCN5A in both K219T-and R190W-CMs in respect 





Figure 23. Reduction of Nav1.5 protein in K219T-CMs. (A) Left: Western blot analysis showing reduced 
level of Nav1.5 channel expression in K219T LMNA-CMs. Data are representative of one cell line per subject. 
Right: quantification of Nav1.5 band intensity calculated as Nav1.5/β-actin ratio (the diagram represents the 
mean of three independent experiments). (B) Left: Representative immunofluorescence images for Nav1.5 
(green) and α-sarcomeric actinin (red) in CNTR- and K219T LMNA-CMs; nuclei are stained with DAPI. 
(Scale bars: 13 µm). Right: quantification of Nav1.5 fluorescence level calculated using ImageJ software (a.u. 








Figure 24. Reduction of SCN5A gene expression in CMs generated from both K219T and R190W 
LMNA-iPSC CMs. Real-time qPCR showing reduced expression of SCN5A gene in CMs generated from 
K219T LMNA-iPSCs (left) and R190W LMNA-iPSCs (right) compared to those differentiated from CNTR 
lines. Data are represented relative to CNTR-CMs and normalized to expression of the housekeeping genes 
18S and HGPRT. Data are relative to CMs differentiated from 2 independent lines from 2 CNTR, 3 K219T-
LMNA and 1 R190W-LMNA. All values are reported as means ± SD. *p<0.05; **p<0.01 (unpaired t-test). 
 
 
Altogether, the obtained results sustain the hypothesis that a reduction of the expression of 
SCN5A gene driven by LaminA/C mutations is at the basis of the diminished sodium currents 




9.5.2. Reduction of SCN5A expression in LMNA-CMs is directly mediated 
by LaminA/C through an epigenetic mechanism 
 
The above described results showed that the sodium channel gene, SCN5A, is differentially 
expressed at both mRNA and protein levels in CNTR-CMs and LMNA mutated-CMs 
(K219T and R190W mutations). To investigate how LaminA/C mutations can affect the 
expression of this gene, we next assessed the occupancy of its promoter by Chromatin 
Immunoprecipitation (ChIP) assay. 
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Figure 25-A shows the results of ChIP against LaminA/C and its binding to the 
Transcriptional Start Site (TSS) of SCN5A and indicates an enrichment of LaminA/C at this 
genomic locus in K219T-CMs compared to CNTR-CMs. On the contrary, LaminA/C 
resulted to be equally enriched in both experimental conditions (CNTR and K219T–CMs) 
at the TSS of SCN10A, DEFA3 and DEFA4 genes (Fig.25-A), which were evaluated as 
known genomic targets of LaminA/C. No enrichment of the protein is instead detectable at 
the TSS of the JUN gene, used as control of the specificity of the antibody, in both 
experimental samples. These findings confirmed the specificity of LaminA/C binding to 
SCN5A locus in K219T-CMs and strengthened our hypothesis that the mutated protein is 
directly involved in regulating the expression of the gene. To further characterize the 
mechanism behind SCN5A regulation, we performed ChIP analyses of two histone markers 
indicative of transcriptional repression – tri-methylated lysine 27 on histone 3 (H3K27me3) 
and tri-methylated lysine 9 on histone 3 (H3K9me3), and of one marker of transcriptional 
activation – tri-methylated lysine 4 on histone 3 (H3K4me3). Results in the Figure 25 (-B 
and –C) showed an enrichment of the two repressive marks at the TSS of the SCN5A gene 
in K219T-CMs; in contrast, H3K4me3 was enriched in CNTR-CMs (Fig. 25-D). Again, 
these findings support the hypothesis that diminished sodium current density in mutated 






Figure 25. Lamin A/C mutation induces SCN5A repression through epigenetic regulation at its 
promoter. (A) ChIP for Lamin A/C, indicating increased binding of LaminA/C to the promoter region of the 
SCN5A gene in K219T-CMs. No enrichment was detectable for JUN, used as a negative control region for the 
ChIP experiment. SCN10A, DEFA3 and DEFA4 genes were used as positive control regions for the ChIP 
experiments. (B) ChIP for the histone modification H3K27me3, showing an enrichment of the repressive 
histone marker at the SCN5A gene promoter in K219T-CMs, supporting the reduced expression of the gene 
detected in these cells. NEURO D was used as positive control region for the antibody. (C) ChIP for H3K9me3, 
showing enrichment of this repressive marker at the promoter region of the SCN5A gene in K219T-CMs. The 
marker was equally enriched on the NANOG promoter region of CNTR and K219T-CMs, used as control. (D) 
ChIP for H3K4me3, showing enrichment of this active marker at the promoter region of the SCN5A gene in 
CNTR-CMs, and thus supporting active transcription of this gene in control cells. Analysis of deposition of 
H3K4me3 marker at TNNC1 and ACTN2 loci served as a control for the antibody. Data are presented as a 
percentage of input chromatin precipitated and relative to 2 independent iPSC-clones from each subject. All 




To further corroborate the specific action of Lamin A/C on the regulation of SCN5A among 
the other important genes of the cardiac conduction pathway, we also determined the 
expression levels of those encoding proteins that play key roles in cardiac conduction (i.e. 
CX40, CX43, TBX3, TBX5) and assessed Lamin A/C binding at their promoters. Results from 
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these experiments showed no significant changes in the expression of those genes between 
CNTR and K219T-CMs and no differences in Lamin A/C enrichment at their promoters 






Figure 26. Epigenetic modulation of genes involved in cardiac conduction. (A) Realtime qPCR for genes 
encoding proteins with a key role in cardiac conduction, namely CX40, CX43, TBX3 and TBX5, showing no 
significant differences in their expression levels between CNTR-CMs and K219T-CMs. (B) ChIP for 
LaminA/C followed by real-time qPCR of the immunoprecipitated DNA, assessing the binding of LaminA/C 
at the promoter region of the genes analysed in A. No significant enrichment was detectable at any of the 
analysed genes. CX43 has not been included in the graph since values from real-time PCR were undetectable 
in both conditions. Data are presented as a percentage of input chromatin precipitated and relative to 2 




Nuclear lamins are also implicated in tethering heterochromatin to the nuclear lamina 
(Deniaud and Bickmore 2009; Solovei, Wang et al. 2013); these interactions occur through 
large Lamin-Associated Domains (LADs) in chromatin and are predominantly associated 
with transcriptional silencing (Guelen, Pagie et al. 2008; Luperchio, Wong et al. 2014). 
LADs are mostly cell-specific and may be distinguished into constitutive (cLADs) and 
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variable (vLADs). The latter correspond to LAD borders and have been shown to be marked 
by H3K27me3 and to dynamically shift to and from the nuclear periphery during 
development, determining distinct gene expression outcomes (Yanez-Cuna and van Steensel 
2017).  
Since SCN5A has been reported to locate in close proximity to SCN10A and SCN11A, both 
mapping in a LAD (Lund, Oldenburg et al. 2013), we next determine whether chromatin 
remodelling (re-localization of the LADs) is occurring in presence of LMNA mutations and 
analyse the LaminA/C binding at this genomic locus during the differentiation of iPSC into 
CMs. We found that, in CNTR-CMs, LaminA/C interact with the SCN5A promoter at early 
stages of cardiac differentiation, but that binding was lost from day 12. In contrast, in 
K219T-CMs such binding was maintained throughout differentiation (Fig.27-A) and, later, 
in terminally differentiated CMs. This finding supports the hypothesis that SCN5A is 
included in a differentiation-regulated LAD, and is consistent with ChIP-seq data previously 
reported in other cell types (Lund, Oldenburg et al. 2013) and with the cardiac-specific 
expression of the SCN5A gene.  
In addition, to visualize the nuclear localization of SCN5A gene, we performed 3D-DNA 
immuno-FISH (Fluorescence In Situ Hybridization) as previously described (Reddy, Zullo 
et al. 2008). Figure 27-B is illustrates the methodology employed to build the 3D distance 
map with ImageJ software and to assign a position to the gene of interest in the analysed 
iPSC-CMs nuclei. Results from this analysis showed a preferential positioning of SCN5A 
gene at the nuclear periphery in K219T-CMs when compared to CNTR cells (Fig. 27-C), 
further supporting the notion that LaminA/C regulates SCN5A gene expression and that 








Figure 27. Epigenetic modulation of SCN5A promoter during cardiac differentiation and analysis of the 
nuclear positioning of SCN5A locus. (A) ChIP against Lamin A/C, showing the dynamics of Lamin A/C 
enrichment at the TSS of the SCN5A gene during cardiac differentiation (from days 0 to 12). For this analysis, 
two-way Anova was used as the statistics test. Data are presented as a percentage of input chromatin 
precipitated and relative to 2 independent iPSC clones from each subject. All values are reported as means ± 
SD, if not differently specified. **p<0.01, ns: not significant. (B) Strategy used for 3D-FISH data analysis. 
Left: images were acquired using confocal microscope. The green circle indicates the Lamin A/C, while the 
magenta spots the genomic region relative to the SCN5A gene. The acquired z-stacks images were analysed 
using ImageJ software. Right: Using 3D-distance map function, on DAPI channel, we calculated the distance 
of SCN5A spots from nuclear periphery (cyan), in each CM nucleus; (C) 3D-FISH experiment detecting Lamin 
A/C (green) and the SCN5A gene (magenta) with an antibody and a DNA probe respectively. Left: 
representative images of nuclei from CNTR and K219T-CM preparations (Scale bar: 9 µm). Magnified box 
shows the colocalization of the SCN5A probe at the nuclear lamina. Right: Analysis of the distance from the 
nuclear lamina, showing preferential localization of the SCN5A probe (magenta) at the nuclear periphery in 
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K219T-CMs vs CNTR. Quantification was carried out using a specific plug-in of the ImageJ software (CNTR: 





To corroborate the obtained results, we also investigated the role of LaminA/C in vivo on 
heart tissue sections from the same patients carrying the K219T mutation (Fig. 28-A). 
Through molecular studies targeting both, the Nav1.5 protein and its encoding gene SCN5A, 
we confirmed a reduced expression of Nav1.5 sodium channel in heart tissue sections from 
patients carrying the K219T mutation in respect to control hearts (Fig. 28-B-C); furthermore 
pathology tissue chromatin immunoprecipitation (PAT-ChIP) experiments showed an 
increased binding of LaminA/C at the TSS of SCN5A in heart sections from K219T patients 
compared to controls (Fig. 28-D). Overall these results further strengthen the hypothesis that 
the reduction of sodium currents is dependent upon diminished expression of the SCN5A 









Figure 28. Analysis of heart tissue sections. A) Graphic representation of the starting samples used to 
perform cardiac tissue investigations. (B) Immunostaining of paraffin-embedded heart sections from patients 
carrying the K219T mutation on LaminA/C (bottom panels) and from control subjects (top panels) targeting 
the Nav1.5 sodium channel (red); nuclei were stained with DAPI. (C) Histogram showing the quantification of 
the red fluorescent signal, corresponding to the Nav1.5 protein, confirming its reduced expression also in 
K219T-LMNA patient hearts (a.u. arbitrary unit). (D) PAT-ChIP analysis of heart sections from patients 
carrying the K219T mutation on LMNA (red bar) and from control subjects (black bar), showing increased 
binding of LaminA/C at the SCN5A gene promoter region in K219T-CMs. Chromatin was immunoprecipitated 
with an antibody against LaminA/C and the resulting DNA was analysed by real-time qPCR and presented as 
a percentage of input chromatin precipitated for the indicated region. All values are reported as means ± 
SD.*p<0.05; ***p<0.0001 (unpaired t-test). Data are relative to 2 independent iPSC-clones from each subject. 
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9.5.3.  LaminA/C cooperates with PRC2 complex in regulating SCN5A 
gene transcription   
 
Interaction between the LaminA/C and chromatin is widely recognized and may occur 
directly or through chromatin binding factors (Wilson and Foisner 2010). The DNA Adenine 
Methylation-based Identification (Dam-ID) first, and ChIP-sequencing experiments (ChIP-
seq) afterwards, have allowed the discovery and the investigation of the LADs regions 
(Guelen, Pagie et al. 2008). However, how LAD regions are regulated in disease and 
mechanisms by which they influence gene expression remains poorly understood. According 
with published studies, LaminA/C epigenetic signature is associated with H3K27me3 profile 
(Harr, Luperchio et al. 2015; van Steensel and Belmont 2017), in particular at the vLADs. 
This epigenetic modification is specifically catalysed by Polycomb Repressive Complex 2 
(PRC2). Cesarini E. and colleagues recently described a tissue-specific cross-talk between 
LaminA/C and PRC2 in regulating gene transcription (Cesarini, Mozzetta et al. 2015), and 
showed that this is involved in controlling the expression of a large number of genes during 
differentiation of muscle cells. Based on these premises and on our results showing an 
enrichment of H3K27me3 at the SCN5A promoter, we next determined whether the SCN5A 
expression could be modulated by a cooperation between PRC2 and LaminA/C. We thus 
evaluated the binding of Suz12, a subunit of PRC2, to the SCN5A promoter by ChIP and 
found an increased binding of this protein in K219T-CMs (Fig. 29-A). This is indicative of 
a potential interaction between LaminA/C and PRC2 in modulating transcription in CMs. 
To test this, we performed immunoprecipitation (IP) experiments against LaminA/C in 
CNTR and K219T iPSC-CMs to assess the direct interaction with PRC2. Results showed a 
higher amount of EZH2 (Enhancer of zeste homolog 2, the catalytic subunit of PRC2) bound 
to LaminA/C in mutant CMs compared to the controls, indicating a higher binding affinity 
of mutant LaminA/C to PRC2 (Fig 29-B). This finding was confirmed also on 
undifferentiated iPSCs following lentiviral-mediated overexpression of either WT- or 
K219T-Lamin A/C, in which IP experiments showed an increased amount of Ezh2 bound to 
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mutant LaminA/C with respect to the wild-type protein (Fig. 29-C). These findings support 




Figure 29. LaminA/C-PRC2 interplay in the regulation of SCN5A transcription. (A) ChIP against Suz12 
(a PcG protein of the PRC2 complex), showing an enrichment of the protein at the SCN5A gene promoter 
region in K219T-CMs. No significant differences were detectable at the NEURO D promoter, used as positive 
control for the antibody. Data are presented as a percentage of input chromatin precipitated and are relative to 
2 independent iPSC lines from each subject. (B-C) Western blot analysis of co-immunoprecipitation (co-IP) 
targeting LaminA/C and the PRC2 subunit Ezh2 conducted on CNTR and K219T-CMs (B) and on control 
iPSCs transduced with lentiviral vectors carrying either GFP-tagged WT- or K219T-Lamin A/C (C). In both 
experiments, there is a higher binding affinity of mutant K219T-LaminA/C for Ezh2. Nuclear extracts were 
immunoprecipitated with LaminA/C antibody, and inputs immunoblotted and hybridized with Ezh2 antibody. 
An unrelated IgG antibody was used as negative control. All values are reported as means ± SD.**p<0.01; ns: 





Next, we also evaluated the expression of the two proteins by Super Resolution Microscopy; 
results from these experiments confirmed the previous Co-IP studies and showed an 
increased co-localization of the two proteins in K219T-CMs (Fig. 30).  
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Figure 30. 3D-STED super-resolution microscopy for LaminA/C and Suz12. (A) 3D-STED super-
resolution microscopy for LaminA/C and Suz12. On the left, a representative image of a nucleus stained for 
the two proteins. The magnified box shows the co-localization of the two proteins (visible as yellow spots). 
Panel on the right show the strategy used to analyse the number of protein colocalization voxels, using the 
“colocalization channel building” function of Imaris software. (B) The graph shows the quantification of the 
voxels of colocalization of the two proteins: interaction was higher in K219T-CMs vs CNTR-CMs (n=16 cells 
per condition). All values are reported as means ± SD.*p<0.05 (unpaired t-test). 
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In addition, analysis of the distribution of PRC2 (alone or bound to LaminA/C) showed 
substantial differences in the global localization-profiles in CNTR and K219T-CMs, 
suggesting a different dynamics of the proteins in the two conditions (Fig.31). In detail, we 
found a proportion of the PRC2-LaminA/C complex in closer proximity to the nuclear 
periphery in K219T-CMs compared to CNTR cells (Fig 31-A-B). This finding fits well with 
results from 3D-FISH experiments, which locate the SCN5A locus preferentially at the 
nuclear periphery in mutant CMs, and sustains the notion that PRC2 and LaminA/C 
cooperate to regulate SCN5A transcription by simultaneously binding to its promoter at the 
nuclear periphery. Of note, we also found that a subpopulation of the complex was 
significantly relocated towards the nuclear interior in K219T-CMs (Fig. 31-B and C), further 
supporting the emerging view that global rearrangement of the two proteins occurs in the 





Figure 31. Assessment of PRC2-LaminA/C complex distribution into iPSC-CMs nucleus. (A) Strategy to 
determine the distance of PRC2-LaminA/C complex from the nuclear periphery. For this analysis, 3D-STED 
microscopy colocalization channel acquisitions (data from Fig. 3.1.3.6) were used and the “distance 
transformation” function of Imaris software was applied to z-stack images. Top: representative images of 
CNTR and K219T-CMs nuclei (scale bar: 2µm). Grey spots indicate LaminA/C fluorescence, selected as the 
outside ring and serving as the “nuclear edge”; the distance transformation function was run on the LaminA/C 
channel, and the distances of the PRC2/LaminA/C colocalization calculated. The coloured bar indicates the 
relative position of the spots to the nuclear edge: the farthest positions are in red and the closest ones in violet. 
Bottom: strategy used for data representation. Distances were scored in three zones, designated as 1, periphery 
(from 0 to 2.15 µm, indicated in white); 2, middle (from 2.15µm to 4.3µm, indicated in light grey); and 3, 
central zone (from 4.3 µm to 6.45 µm, indicated in dark grey). As above, the distance of every single 
colocalization spot was calculated from the “nuclear edge”, identified as a ring of spots of LaminA/C. (B) 
Distribution profile of PRC2-Lamin A/C colocalization in nuclei of CNTR and K219T-CMs. The box plot 
shows the distribution of PRC2/Lamin A/C complex within the nucleus in the three selected zones. Values are 
median ± SD of 5 cells per conditions (***p<0.0001; **p<0.01, two-way ANOVA). (C) Distribution profiles 
of PRC2-LaminA/C complex (left) and PRC2 (right). Data show significantly different dynamics of the two 
proteins in CNTR (black line) and K219T-CMs (red line), with a subpopulation of the PRC2/LaminA/C 
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complex in K219T-CMs (top) localized closer to the nuclear periphery (zone 1) than in CNTR-CMs, and 
another subpopulation relocated towards the nuclear interior (zone 3). Distribution relative to PRC2 itself 
shows profiles similar to those obtained from the colocalization signals above. The distances to the nuclear 
periphery were calculated relative to the “nuclear edge”, identified as a ring of spots of LaminA/C, and 
represented as frequency distribution profiles using cubic spline of histogram with 0.2 µm Bin. Relative 
distributions were evaluated in three selected zones: 1, periphery (white); 2, middle (light grey); and 3, central 
(dark grey). Values are median ± SD of 5 cells per condition (***p<0.0001; **p<0.01, two-way ANOVA). 
 
 
9.5.4. K219T LaminA/C overexpression in CMs from control ES cells 
recapitulates functional and molecular characteristics of parental 
K219T-CMs 
 
To further prove that the reduction of Na+ current density and the respective downregulation 
of the SCN5A gene are caused by the K219T LaminA/C mutation, we performed a series of 
gain of function studies in CMs derived from the RUES2 human ES cell line by 
overexpressing the mutant K219T-LaminA/C.  
We first generated a C-terminal tagged EGFP (enhanced green fluorescent protein)-
fusion lentiviral construct expressing LaminA/C carrying the K219T mutation (LaminA/C-
EGFP); the same construct expressing the wild type LaminA/C and a lentiviral vector 
carrying the empty GFP cassette were used as controls (Fig. 32-A). Then, to mimic the 
heterozygous disease condition, RUES-CMs were transduced at day 6 of differentiation, 
stage at which LaminA/C begins to be expressed. Analyses by patch clamp showed a 
reduction of the peak Na+ current density in cells expressing the mutation, positive for GFP 
expression (at -30mV holding potential, 29.8% decrease vs CNTR-CMs indicated as GFPneg; 
Fig. 32-B-D). No changes of the voltage dependence of activation and inactivation 
parameters (half-maximal voltage [V1/2] and slope factor [k]) between the conditions (Fig. 
32-C). Instead, overexpression of either the empty GFP vector or the vector encoding wild-
type LaminA/C (WT LaminA/C-GFP) did not produce any effect on Na+ current density in 
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RUES2-CMs (Fig. 32-B-C-D), providing an additional demonstration that the observed 
phenotype is causally linked to the K219T LaminA/C mutation. 
 
Figure 32. Overexpression of K219T-LMNA in the RUES ESC lines recapitulates the phenotype of 
parental K219T-CMs. (A) Lentiviral vectors expressing the C-terminal GFP-tagged K219T-LaminA/C, wild 
type LaminA/C and empty vector, used for the overexpression experiments. (B) Left panel: examples of Na+ 
current traces recorded in GFPneg and empty-GFPpos CMs (top); K219T-GFPpos and LMNA-WT-GFPpos CMs 
(bottom), (Scale bar, 2ms, 50pA/pF). Right panel: I-V curves constructed from average peak sodium current 
density as a function of voltage command measured in the four conditions described above (GFPneg: n=14; 
K219T-GFPpos: n=21; empty -GFPpos: n=15; LMNA-WT-GFPpos: n=14) showing significant sodium current 
reductions in K219T-GFPpos cells, while there were no changes compared to control cells (GFPneg) induced by 
overexpression of either the empty-GFP vector or the one expressing wild-type LaminA/C. All values are 
reported as means ± SD. *p <0.05; **p <0.005 and £p <0.05; ££p <0.005 (unpaired t-test). (C) Voltage 
dependences: steady state activation (GFPneg: n=14; K219T-GFPpos: n=21; empty-GFPpos: n=15; LMNA-WT-
GFPpos: n=14)/inactivation (GFPneg: n=11; K219T-GFPpos: n=17; empty-GFPpos: n=12; LMNA-WT-GFPpos: 
n=12) curves. (D) Na+ current density, measured at -30 mV, in K219T-CMs (91.58 ± 30.69 pA/pF) relative to 
CNTR-CMs (156.12 ± 33.73 pA/pF) and K219T-GFPpos (115.20 ± 43.35 pA/pF), LMNA-WT-GFPpos CMs 
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(156.22 ± 81.41 pA/pF) and empty-GFPpos CMs (159.76 ± 63.31 pA/pF) relative to GFPneg CMs (164.02 ± 
43.18 pA/pF) all expressed as a percentage. Values for K219T- (red bar) and CNTR- (black bar) CMs are 
reported from Figure 21 as references for evaluating the relative effect in the analysed overexpression 





Functional data were also confirmed at the molecular level, by assessment of the expression 
of SCN5A gene by RT-PCR after cell sorting: the results showed levels of expression 
significantly lower in RUES-CMs overexpressing the mutation (GFPpos) in respect to the 




Figure 33. Molecular investigation of RUES ESC lines infected with K219T-LMNA lentivirus. (A) Gating 
strategy and cell populations (GFPpos- and GFPneg) selected for the sorting are shown. (B) RT-PCR comparing 
SCN5A gene expression in GFPneg and K219T-GFPpos CMs isolated through FACS. Data are represented 
relative to GFPneg samples and normalized to expression of HPRT and 18S housekeeping genes. All values are 





9.5.5. Isogenic control lines 
 
In order to unequivocally establish genotype-phenotype correlations and determine the 
mechanisms behind the pathology, we combined iPSC technology with a CRISPR/Cas9 
genome editing approach and generated iPSC lines, in which the LMNA mutations have been 
corrected (isogenic lines). This part of the study (strategy design) has been conducted in 
collaboration with the laboratory of Prof. Charles E. Murry, University of Washington 
(Seattle, WA, USA).  
As first step we identified closest “TTAA” sites to both mutations (about 130bp from 
mutations sites), in order to minimize the editing “scar”. Then, we designed single guides 
RNA (sgRNAs) spanning the TTAA site for each targeting sequence, and cloned them into 
the enhanced specificity SpCas9 (eSpCas9) plasmid (Fig.35). Targeting vectors was 
constructed from the MV-PGK-Puro-TK plasmid, containing a piggyBac transposon and 
specific selection cassettes containing both positive and negative selectable markers 
(puromycin resistance and thymidine kinase conferring fialuridine sensitivity). Details of 
lines generation are provided in materials and methods chapter. 
The protocol is adapted from Yusa K et al (Yusa 2013) and the workflow is illustrated in 
Fig.34 A-B. In brief, a vector containing a piggyBac (pbLMNA) selection-cassette was used 
to target LMNA locus, between exon 3 and exon 4. Using CRISPR/Cas9 strategy, the 
pbLMNA vector together with eSpCas9 guide plasmid were transfected into K219T and 




Figure 34. Schematic representation of the workflow for the generation of the isogenic control lines, using the 
piggyBac transposon system. LMNA mutations are indicated by the red star. 
 
 
For the first step, 75,000 iPSCs were seeded in each well of 6-well plate and transfected with 
1 µg of DNA, equally divided between eSpCas9-LMNA and pbLMNA_K219K. Targeted 
cells were drug-selected by adding puromycin at a concentration of 1 µg/ml for the first 4 
days, and then reduced to 0.5 µg/ml. After 10 days, isolated clones were manually picked 
and genotyped (Fig. 36-A). Positive clones were further characterized by Sanger sequencing, 
karyotyped and expanded. To remove piggyBac, K219K_PB_iPSCs were transfected using 
a transposase expression vector (Fig. 34-B). After 1 week cells were negatively selected by 
adding 400 nM of fialuridine to the culture media. Individual clones were isolated after 7 
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days of selection and screened by PCRs (Fig.36-A). Positive clones were sequenced to 
confirm the correction of the LMNA mutation and then analysed for karyotype verification 
(Fig.36-B and -C). In addition, we already generated corrected lines also from LMNA#3 and 
R190W#B clones, which will be included in future investigations and analyses. 
 
 
Figure 35. Schematic view of the gene correction strategy. Upper panel: representation of the endogenous 
“TTAA” site in the third intron of LMNA and located 135 bp upstream to the AAC mutation in exon 4 leading 
to the K219T change, and of the single guide RNA (sgRNA) sequence. The bottom panel gives a schematic 




Figure 36. Characterization of corrected-lines. (A) Genotyping PCRs for the three lines generated from the 
K219T LMNA #1_2 iPSC line. DNA from a control line and the targeting plasmid, have been included as 
controls. (B) Electropherograms of the three isogenic K219T-corrected iPSC lines generated in this study 
(clone #F4, #F5, #F6), showing the specific correction of the mutation. (C) Karyotype analyses of the three 













9.5.6. Correction of the mutation by gene-editing rescues both functional 
and molecular phenotypes of K219T-CMs 
 
Functional analyses by patch-clamp revealed a complete restore of Na+ currents in K219T-
corrected CMs. Indeed, INa density recorded in corrected lines are totally comparable with 




Figure 37. Functional analyses of K219T-corrected isogenic CMs. (A) Left panel: examples of INa traces 
recorded in CNTR- (top), K219T-corrected (top) and K219T (bottom) -CMs (Scale bar, 2ms, 50pA/pF). Right 
panel: I-V curves constructed from average peak sodium current density as a function of voltage command 
measured in the three conditions described above (CNTR: n=23; K219T-corrected: n=14; K219T: n=22), 
showing a significant increase in K219T-corrected cells with respect to the parental mutant CMs. (B) INa 
density, measured at -30 mV, in K219T-corrected CMs (176.94 ± 61.05 pA/pF) relative to K219T-CMs (91.58 
± 30.69 pA/pF) and CNTR-CMs (156.12 ± 33.73 pA/pF) expressed as a percentage. (C) Voltage dependences: 
steady state activation (CNTR: n=23; K219T-corrected: n=14; K219T: n=22); inactivation (CNTR: n=18; 
K219T-corrected: n=12; K219T: n=17) curves. All values are reported as means ± SD. *adj. p <0.05; 




Remarkably, reestablishment of sodium current density corresponded to a significant 
enhancement of SCN5A transcription in the K219T-corrected cells (Fig. 38-A); restoration 
of the functional and molecular phenotype was also coupled with decreased binding of 
LaminA/C to the SCN5A promoter in K219T-corrected CMs (Fig. 38-B), further supporting 
the hypothesis that impairment of SCN5A expression and the consequential effect on the Na+ 




Figure 38. Molecular phenotype of K219T-corrected isogenic CMs. (A) RT-PCR showing that SCN5A gene 
expression in CMs generated from K219T-corrected-iPSCs is restored to levels as in CNTR-CMs. Data are 
represented relative to CNTR-CMs and normalized to the expression of the housekeeping genes 18S and 
HGPRT. (B) ChIP against LaminA/C, showing loss of LaminA/C binding at the SCN5A promoter region in 
K219T-corrected CMs vs mutant K219T-CMs. Levels of LaminA/C binding are instead indistinguishable from 




On the whole, our findings support a model in which mutated LaminA/C disturbs the correct 
transcription of SCN5A by favouring the binding of PRC2 to its promoter, leading to 






Figure 39. Proposed pathogenic mechanism of action of K219T_LaminA/C in human iPSC-derived 
CMs. Left: Healthy CMs. The SCN5A genomic region is localized in the nuclear interior and is actively 
transcribed; in this cellular state, the Nav1.5 sodium channel density at the plasma membrane is sufficient to 
assure proper impulse propagation. Right: Laminopathic CMs. K219T_LaminA/C and PRC2 bind each other 
with high affinity and are enriched at the SCN5A promoter region, where the H3K27me3 (catalysed by PRC2) 
and H3K9me3 repressive histone marks are also present. In this repressive environment, this genomic region 
is preferentially sequestered at the nuclear periphery. As a result, SCN5A gene transcription is repressed, 
leading to reduced expression of the Nav1.5 sodium channel at the plasma membrane, which, in turn, affects 
conduction velocity which results reduced in this condition. This regulatory mechanism may be at the basis of 









9.6. Use of LMNA-CMs as a platform for drug testing: a 
proof-of-concept experiment 
 
Beyond their utility for studying mechanisms of disease, iPSCs have been extensively 
proven to be a reliable tool also for pharmacological testing (Takahashi and Yamanaka 
2016), as long as a good readout may be identified.  
In order to validate the translational power of the generated models and the reliability of the 
main functional outcome emerged from our studies, namely reduction of sodium currents, 
as pharmacological readout, we perform a series of proof-of-concept experiments and tested 
the effect of a small molecule, called Remodelin, on this functional parameter. 
Remodelin is an inhibitor of the N-acetyltransferase 10 enzyme (NAT10), that has been 
shown to efficiently improve nuclear abnormalities of laminopathic cells, either depleted for 
LaminA/C or from patients affected by progeria (HGPS -Hutchinson-Gilford Progeria 
Syndrome) (Larrieu, Britton et al. 2014). Remodelin has been also shown to enhance lifespan 
of HGPS mice and to ameliorate the associated cardiac pathologies in vivo (Balmus, Larrieu 
et al. 2018). 
Nuclear morphology and chromatin disorganization are also typical signs of cells 
carrying LMNA mutations (Toth, Yang et al. 2005; Galiova, Bartova et al. 2008; Chen, Chi 
et al. 2012) including the one described by us (Roncarati, Viviani Anselmi et al. 2013). 
Exposure of K219T-CMs to Remodelin rescued average peak Na+ currents density, 
increasing it to a level similar to that recorded in CNTR-CMs (Fig. 40-A); indeed, at a 
membrane potential of -30 mV, there was a 60.7% increase in density (Fig. 40-B). While the 
molecular mechanism by which Remodelin is acting in this context is still unknown, this 
finding confirms the importance of nuclear structure on gene expression control, providing 
indirect evidence of the pathogenic mechanism of the K219T LMNA mutation, and suggests 






Figure 40. Treatment with Remodelin restores sodium currents density in K219T-CMs. (A) Left column: 
examples of INa traces recorded in CNTR- (top, left), K219T LMNA- (bottom, left) and K219T LMNA-CMs 
exposed to Remodelin (K219T+Remodelin - middle, right) (Scale bar, 2ms, 50pA/pF). Right panel: I-V curves 
constructed from average peak sodium current density as a function of voltage command measured in the three 
conditions described above. CNTR-CMs: n=23; K219T LMNA-CMs: n=22; K219T LMNA-CMs + Remodelin: 
n= 20. (B) INa density, measured at -30 mV, in K219T LMNA-CMs exposed to Remodelin (186.39 ± 52.96 
pA/pF) relative to K219T-LMNA (91.58 ± 30.69 pA/pF) and CNTR-CMs (156.12 ± 33.73 pA/pF) expressed 









9.7. Effect of LaminA/C mutations on contractile 
pathways: molecular and functional studies 
 
 
9.7.1. K219T LaminA/C mutation modulates genes involved in 
contraction of the cardiac muscle 
 
Based on the results from RNA-sequencing experiments, we next focused on the muscle 
contraction pathway and assess whether the functionality of iPSC-CMs was affected by 
Lamin A/C mutations. From the analysis of transcriptomic data, MYH6, MYBPC3, DES, 
TCAP, TRIM63, TNNT2 emerged as the main mis-regulated genes which encode proteins 
with key functions in muscle contraction.  
In a first instance, we validated the genes selected from the bioinformatics analysis by real 
time RT-PCR and confirmed they were all down-regulated in K219T-CMs compared to the 
CNTR (Fig.41-A). Next, we focused on two of these, TRIM63 and TNNT2 genes, and tested 
whether the down regulation of their expression in K219T-CMs was due to Lamin A/C 
mutation. ChIP experiments against LaminA/C confirmed an enrichment of the protein on 
the promoter region of both TRIM63 and TNNT2 genes in K219T-CMs (Fig. 41-B), 
supporting the hypothesis that LaminA/C is directly involved in the epigenetic control of the 
expression of both genes and that the K219T mutation can interfere with this regulatory 




Figure 41. Effect of LaminA/C mutations on contractility genes. (A) Real-time PCR showing reduced 
expression of genes involved in cardiac contraction in CMs generated from K219T-iPSCs in respect to those 
differentiated from CNTR cells; (B) ChIP analysis in CNTR and K219T-CMs using antibody against 
LaminA/C. The graph shows an increased binding of LaminA/C at the promoter region of TRIM63 and TNNT2 
genes in K219T-CMs. Data are presented as percentage of input chromatin precipitated and relative to 2 




9.7.2. Assessment of contractile properties of LMNA-CMs 
 
In order to establish the impact of LaminA/C mutations on CMs contractility parameters, we 
performed functional analyses using the IonOptix microscope technique (Feaster, Cadar et 
al. 2015; Pointon, Harmer et al. 2015). In the same experimental setting, we evaluated both 
contraction force and intracellular calcium dynamics. To assess the amount of Ca2+, iPSC-
CMs were loaded with Fura-2 acetoxymethyl ester, Fura-2 AM (Molecular Probes Inc, 
Eugene, OR) (Fig. 41-A). Then, spontaneous contractions following electrical (Fig. 42-B) 
or chemical stimulations (Fig. 42-C), were recorded. 
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Figure 42. Schematic representation of the approach used for functional measurements using IonOptix 
system. (A) iPSC-CMs were loaded with FURA-2 (5µM) to measure calcium transients and then, in order to 
perform contraction measurements, CMs from both control and LMNA mutated lines, were recorded with the 
following protocols: the baseline - spontaneous beating - followed by either electrodes stimulation (0.5, 1 and 
2 Hz) (B) or with β-adrenergic agonist isoproterenol (C).  
 
 
To analyse contractility, we employed a cell length IonOptix protocol, instead of the 
commonly used one which is based on evaluation of sarcomere length; this is because of the 
smaller and thinner morphology of iPSC-CMs sarcomeres compared to mouse adult CMs. 
Example of traces from calcium transients and contraction recordings are shown in the 
Figure 43 and have been recorded for each analysed cell. 
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Figure 43. (A) Top: Schematic representation of cell contraction recordings using IonOptix system. Bottom: 
representative trace of iPSC-CMs contraction (CNTR labelled in black and LMNA labelled in red). (B) Top: 
schematic representation of Ca2+ measurements in cells loaded with FURA-2 (an intracellular calcium 
indicator). Bottom: representative trace of intracellular calcium measurements in iPSC-CMs (CNTR labelled 




Results from these experiments are shown in the Figure 44 and indicates a decrease in cluster 
shortening in CMs carrying the LMNA mutations when compared with those generated from 
control iPSCs. Furthermore, mutant CMs fail to respond to electrodes stimulation (0.5Hz, 
1Hz, 2Hz). This data is in agreement with those previously obtained during assessment of 
conduction velocity of K219T-CMs (see Figure 22), reinforcing the concept of a defective 
response to ionotropic stimulation in presence of LaminA/C mutations. Mechanisms behind 




Figure 44. Shortening parameter measured in LMNA- and CNTR-CMs. The graph shows a decrease of 
cluster shortening parameter (an index of contractility) in LMNA-CMs compared to CNTR-CMs. LMNA 

























 The heterogeneous clinical phenotypes of laminopathies represent the main 
limitation for the identification of the molecular mechanisms underlying the disease and for 
the development of effective therapies. Genetically-modified animal models, immortalized 
cell lines and primary human cells have been extensively used to study the effect of 
LaminA/C mutations in different contexts; however, dissection of the mechanisms 
responsible for the disease is still incomplete, especially for those tissues/organs that are of 
difficult accessibility or for which human and animal physiology highly differs, as the heart 
(Arimura, Helbling-Leclerc et al. 2005; Mounkes, Kozlov et al. 2005). 
Our study aimed at overcoming such limitations and developed a model system to dissect 
functional and molecular mechanisms of cardiac defects associated to laminopathies. At the 
heart level, mutation in the LMNA gene cause DCM, usually anticipated by various CSDs 
(Arbustini, Pilotto et al. 2002; Brodt, Siegfried et al. 2013; Zhang, Kieckhaefer et al. 2013). 
Defects of the contractile apparatus represent, together with the conduction abnormalities, 
major clinical phenotypes of laminopathies and have been detected in laminopathic cells 
derived from patients exhibiting skeletal or cardiac disorders. Cellular abnormalities, 
including irregular nuclear shape and susceptibility to electrical stress, were already 
described on laminopathic fibroblasts (Goldman, Shumaker et al. 2004; Scaffidi and Misteli 
2006; Shumaker, Dechat et al. 2006) or iPSC-CMs derived from patients with LMNA-CMP 
(Siu, Lee et al. 2012; Lee, Lau et al. 2017; Chatzifrangkeskou, Yadin et al. 2018). However, 
described mechanisms are still incomplete. 
Here we generated a human model of LMNA-CMP to investigate the role of LaminA/C 
mutations in the proper cellular context: the human cardiomyocytes. To this goal, we 
employed iPSC technology combined with a wide range of different techniques and 
dissected cellular and molecular mechanisms responsible for the disease phenotype. 
First of all, our analyses confirmed an increased size of CMs obtained from K219T- and 
R190W-iPSCs, demonstrating that the generated models are able to recapitulate a typical 
trait of DCM. Furthermore, those cells also display disorganization of the sarcomeric 
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structure by immunofluorescence, which is another key feature of LMNA-CMPs. This is in 
agreement to what already described in iPSC-CMs by other groups, and further support the 
reliability of the employed model for investigating the mechanisms underlying the disease 
(Chatzifrangkeskou, Yadin et al. 2018). 
Electrophysiological characterization by patch clamp highlighted, as major functional 
phenotypes, significant alterations of AP properties of cardiac excitability. In particular, 
maximal upstroke velocity (dV/dtmax) was the major electrical phenotype that emerged 
altered in mutant CMs. This defect was linked to a profound impairment of Na+ current 
density, that leads to cardiac impulse propagation defects.  
Even though a link between LaminA/C mutations and Nav1.5 regulation has been previously 
reported, results emerged from previous studies are contradictory and conducted on other 
cellular systems. Liu et al reported an inhibitory effect of R644C and R190W LMNA 
mutations on Nav1.5 currents in HEK293T cells (Liu, Shan et al. 2016). Conversely, 
Markandeya Y.S. and colleagues described an increased peak of INa and the prolongation of 
action potential duration in ventricular CMs isolated from N195K/N195K homozygous mice 
(Markandeya, Tsubouchi et al. 2016). Our findings get across these discrepancies and 
described this phenotype in a relevant pathophysiological context in humans that is a patient-
specific model of LMNA-CMP generated through differentiation of iPSCs into CMs. 
Density of voltage-gated Na+ current is at the basis of the excitability of the cardiomyocyte 
and is a major determinant of impulse propagation across the myocardium (Grant 2009; 
Rook, Evers et al. 2012). SCN5A gene encodes the main cardiac voltage-gated sodium 
channel α-subunit, Nav1.5; mutations of this gene have been linked to impaired expression 
or function of the Nav1.5 protein and have been associated to various forms of hereditary 
arrhythmias, such as Long QT syndrome type 3 (LQTS3), Lenègre-Lev disease and Brugada 
syndrome (Li, Yin et al. 2018). Alterations of SCN5A gene, and its encoded protein Nav1.5, 
have been also frequently reported in common cardiac disorders, including heart failure, 
further indicating their fundamental role in the regulation of cardiomyocyte excitability 
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(McNally and Mestroni 2017). Moreover, conduction disorders and sudden death also 
represent typical hallmarks of CMP due to LMNA mutation (McNally and Mestroni 2017; 
Nomura 2018). Altogether, these evidences strongly support a pathogenic role of diminished 
Na+ channel expression in the occurrence of the conduction disorders detected in LMNA-
CMs. 
In line with these observations, conduction velocities were also found considerably 
decreased in confluent multicellular strands of K219T-CMs. Cardiac excitation depends on 
both AP generation from individual cells and cell-to-cell conduction of the generated AP. 
This latter event occurs through gap junctions (Kleber and Rudy 2004; Mounkes, Kozlov et 
al. 2005; Veeraraghavan, Gourdie et al. 2014). On this regard, mislocalization or 
misexpression of Connexin-43 (CX-43) have been previously associated to conduction 
defects in LMNA-CMP (Sun, Yazawa et al. 2012; Veeraraghavan, Gourdie et al. 2014; 
Macquart, Juttner et al. 2018). CX-43 is a gap junction protein, which, in the heart, localizes 
at the intercalated disks (end-to-end coupling) of CMs, where it contributes to establish 
intercellular conductance and impulse propagation (Molica, Meens et al. 2014; Kelly, Simek 
et al. 2015; Leybaert, Lampe et al. 2017). In our model, we did not found abnormal 
expression of CX-43 gene; however, we could not exclude the possibility that an anomalous 
localization of the protein may occur, leading to a reduced gap junctional coupling and 
contributing to the conduction defects detected in mutant LMNA-CMs. In support of this, we 
observed that the reduction of CVs in K219T-CMs was more accentuated than the decrease 
in dV/dtmax and Na+ current density registered in single-cell preparations. The stronger 
difference detected on CV than on the excitability parameters may be due to an additive 
effect of the intercellular conductance pathway to the sodium-based excitability 
disturbances. 
Given the major role of A-type lamins in transcriptional regulation and chromatin 
organization, we hypothesize that an alteration of the transcriptional program caused by 
mutations in LaminA/C may underlie the functional defects found in LMNA-CMs. 
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Molecular studies targeting sodium channel protein Nav1.5 and its encoding gene, SCN5A, 
revealed a significant reduction of both protein and transcript in mutant CMs accompanied 
by an increased binding of LaminA/C and deposition of the H3K9me3 and H3K27me3 
markers at the promoter of the gene. These evidences strongly support the hypothesis of an 
epigenetically-mediated modulation on SCN5A gene driven by LaminA/C and defective in 
case of occurrence of LMNA mutations. Along this line, it is now widely recognized that, 
besides its structural role in the nucleus, LaminA/C take also part in the control of gene 
transcription either by its direct interaction with chromatin and DNA or through the binding 
to specific chromatin associated proteins and transcription factors (Johnson, Nitta et al. 
2004; Reddy, Zullo et al. 2008; Zuleger, Robson et al. 2011; Harr, Luperchio et al. 2015). 
When LaminA/C gene is defective, these interactions may result altered (Worman and 
Courvalin 2002; Wilson and Foisner 2010), and changes in specific gene transcription 
patterns are likely to occur as major consequences.  
The interaction between lamins and chromatin mainly occurs through the LADs, namely 
Lamin Associated Domains, which are regions of the genome of about 0.1-10Mb that 
include mostly, but not exclusively, repressed genes. Specific LADs distribution profiles 
have been found in many different cell types and proposed to contribute to define cell 
identity; in addition to this, recent studies have shown rearrangements of LADs occurs in 
disease and may define a specific disease state (Guelen, Pagie et al. 2008; Kind, Pagie et al. 
2013; Lund, Oldenburg et al. 2013; Cesarini, Mozzetta et al. 2015; Perovanovic, Dell'Orso 
et al. 2016). It is therefore highly probable that changes in gene expression occurring in cells 
from patients carrying different types of LaminA/C mutations (i.e. progeroid disorder, 
lipodystrophies and muscle dystrophy) were due to gain/loss of LADs, affecting genome 
architecture (Perovanovic, Dell'Orso et al. 2016; Paulsen, Sekelja et al. 2017). Interestingly, 
SCN5A was also found located in a LAD in other cell types (Lund, Oldenburg et al. 2013); 
as such it represents a potential target gene which expression may be altered in case of LAD 
remodelling. The analysis of LaminA/C binding at the SCN5A promoter locus during 
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differentiation of iPSC into CMs, confirmed this hypothesis, supporting the notion that LAD 
rearrangement may occur in presence of the LMNA mutation also in CMs. Therefore, our 
findings strongly sustain a view by which the epigenetic regulation of SCN5A mediated by 
LaminA/C may be a cause of the disease.  
More in detail, in the model we propose here, mutant LaminA/C form a repressive complex 
with PRC2, which acts inhibiting SCN5A gene transcription through the repressive action of 
LaminA/C itself and the deposition of the H3K27me3 repressive marker at the promoter of 
the gene. In addition to this, SCN5A gene also resulted preferentially located at the nuclear 
periphery, in a repressive environment. 
Therefore, the proposed model sees two additional “actors” involved in the modulation of 
the expression of SCN5A gene: PRC2 and the nuclear periphery. Results from 3D-FISH 
experiments indicated a significantly different nuclear localization occurring in K219T-
CMs, with the SCN5A gene probe preferentially detected at the nuclear periphery. This 
further contributes to determine a repressive environment, leading to a down-regulation of 
sodium channel gene and resulting in diminished sodium current, and may be indicative of 
changes in LADs conformation.  
Additionally, together with LaminA/C, we also found an enrichment of PRC2 at the same 
SCN5A promoter locus. Results from Super Resolution Microscopy (STED) experiments 
revealed a higher colocalization of LaminA/C and PRC2 in mutant CMs and a different 
distribution of the PRC2/LaminA/C complex in presence of the mutation, suggesting that a 
single point mutation in LMNA could differentially mediate the specific affinity of 
LaminA/C protein for other binding factors, as the Polycomb complex. STED experiments 
have also shown a portion of PRC2/LaminA/C complex constrained to the nuclear periphery 
in K219T-CMs, further supporting the view that a regulatory circuit involving LaminA/C 
and PRC2 is acting on SCN5A gene at that cellular compartment. However, it is worth to 
point out that a significant portion of the complex has also been identified in the nuclear 
interior. This is line with previous studies indicating a link between LaminA/C and the intra-
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nuclear localization of PcG proteins and with their preferential nuclear 
compartmentalization in cells lacking LaminA/C (Marullo, Cesarini et al. 2016). 
Based on the functional interaction of nucleoplasmic LaminA/C with PRC2, previously 
described by Marullo et al, and on the discrepancies in proteins’ distribution profiles found 
between K219T–and CNTR-CMs, we hypothesized that differences in proteins’ interaction 
affinity may exist in the context of the pathology. Co-IP experiments confirmed this 
hypothesis and showed a higher binding of LaminA/C to PRC2 in K219T-CMs, indicative 
of the higher affinity of K219T mutated form of LaminA/C for PRC2. This is also in line 
with the similar distribution profiles of the two proteins in the 3D nuclear space and with the 
different proteins’ dynamics we observed.  
The concept that a correlation between LaminA/C mutations and protein dynamics may 
exist is not new and it has been recently described (Serebryannyy, Ball et al. 2018). In this 
study, the authors illustrated a new method, called single molecule tracking (SMT) 
technology, to distinguish the behaviour of LaminA/C protein carrying different mutations 
within the nuclear space at the single-cell level and showed substantial differences in the 
distribution of the LaminA/C mutants, identifying peripheral and nuclear interior 
subpopulations.  These results are in line with our 3D-STED findings and reinforce the 
notion that changes of protein’s dynamics may occur in presence of different LMNA 
mutations in CMs nuclei. This proteins’ relocation within the nucleus is expected to act in 
the control of gene transcription in a cell- specific and time-dependent manner. 
In view of these global rearrangements throughout the nucleus, we cannot exclude an effect 
on other disease-relevant genes, besides the main identified target SCN5A, in our cellular 
model; on the contrary, transcriptional reprogramming is likely to occur at the global level 
in cardiac cells, leading to dis-regulation of genes involved in different pathways and 
disease.    
In agreement with this assumption, results from RNA-seq analysis in mutant and control 
CMs showed a differential expression of genes involved in cardiac contraction and cell 
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metabolism, other two relevant pathways for LMNA-CMP. Preliminary data from gene 
expression and ChIP performed on two of the downregulated genes of the contraction 
pathway indicated a mechanisms of regulation similar to the one described for SCN5A, 
showing an enrichment of LaminA/C protein on their promoter in K219T-CMs in respect to 
the controls. These additional findings further support the solidity of the mechanisms 
proposed for SCN5A regulation and, more generally, strengthen the hypothesis that 
LaminA/C can function as a docking platform and selectively modulate the expression of 
specific target genes. 
Improving the knowledge of the molecular basis underlying the LMNA-CMP clinical 
phenotype constitutes a mandatory requisite to enhance the patients’ lifespan and to improve 
currently available therapeutic approaches, still inadequate to specifically treat LMNA 
patients. Available medical treatments are, in fact, more directed to control symptoms and 
to prevent disease progression other than to cure the origin of the disease.  
Besides the important mechanistic advancement, results obtained in this Thesis work also 
allowed to identify SCN5A gene and Na+ current density as new pharmacological targets for 
conduction defects in LMNA-CMPs.  
It is indeed conceivable that pharmacological modulation of sodium channel activity or 
expression, for example by sodium channel agonists, epigenetic drugs or gene replacement, 
will lead to an improvement of the functional phenotype in these cells. This concept is further 
sustained by results from K219T-corrected lines that demonstrated the casual link between 
K219T-LMNA mutation, SCN5A gene transcriptional regulation and Na+ currents, showing 
the rescue of the electrophysiological phenotype (normalization of Na+ currents density) in 
isogenic K219T-corrected LMNA –CMs and the reestablishment of SCN5A expression level 
as in the controls through the restore of its epigenetic regulation as in the healthy condition.  
A further confirmation of SCN5A as potential therapeutic target comes from preliminary 
data by us that show a beneficial effect of lentiviral-mediated overexpression of SCN5A gene 
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in mutant K219T-CMs on both, sodium currents density and maximal upstroke velocity (not 
shown). 
Finally, we also provided evidence that iPCS-derived CMs represent a reliable platform for 
drug testing and that sodium current density may be successfully employed as functional 
outcome, as indicated by the experiments on Remodelin (Larrieu, Britton et al. 2014), in 
which the functional defects of LMNA-CMs were blunted by restoring sodium current 
density to a normal level. While the molecular mechanism by which Remodelin is acting in 
this context is still unknown, we assume that it can act either on gene expression by rescuing 
the morphology of the nucleus, and consequently by reorganization of chromatin, or by 
shuttling the Na+ channels that are left at the plasma membrane through a microtubule-
mediated mechanism (Shen, Zheng et al. 2009). 
NAT10 activity was indeed linked to microtubules stabilization, so that the mechanism of 
action of Remodelin in CMs may rely on modulation of the nucleo-cytoplasmic transport 
through midbody and microtubules machinery. In line with this hypothesis, it has been 
recently proposed that NAT10 inhibition could restore the Transportin-1/NPC protein 
complex (TNPO1-NUP153) translocation into the nucleus in HGPS, resulting in the proper 
assembling of nuclear pore complexes (NPCs) and in the restore of the other NPC-dependent 
activities (Larrieu, Vire et al. 2018).  Therefore, it is reasonable that also LMNA mutations 
could lead to defects in the nuclear-cytosol exchanges through microtubules machinery and 
that the transcriptional changes as well as the different protein dynamics and the altered 
interaction affinity showed in mutant CMs, could be the downstream effects of LMNA 
mutations. 
Interestingly, Remodelin has been also shown effective in vivo in ameliorating the HGPS 
phenotype by enhancing the healthspan in LmnaG609G HGPS mouse model (Balmus, Larrieu 
et al. 2018); this further sustains the potential validity of this molecule in treatment of LMNA 
patients. On this regard, we have accumulated preliminary evidence in CNTR-CMs (data 
not shown), showing a boost effect of Remodelin on sodium channel and AP parameters, 
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suggesting that inhibition of NAT10 can be beneficial for CMs fitness. These data also 
support the potential of Remodelin as specific enhancer of Nav1.5 currents, rather than as a 
specific drug for LMNA-CMP. Further investigations on the molecular mechanisms behind 
the observed functional effects will shed light on the specific pathways targeted by 
Remodelin in the CMs and help establishing its actual therapeutic value for cardiac diseases. 
 In conclusion, this thesis describes a new pathogenic mechanism for LMNA-CMP, 
dependent upon transcriptional changes driven by mutant LaminA/C. In particular, for the 
conduction defects, one of the most severe LMNA-CMP associated phenotype, SCN5A was 
identified as the major target gene. Whether the described effect on this gene is selective for 
certain mutations affecting specific protein domains or is more broadly linked to altered 
LaminA/C conformation is still unclear and needs further investigation. The identification 
of a conserved LaminA/C-dependent epigenetic mechanism that regulates transcription of 
genes belonging to other two disease-relevant pathways, cardiac metabolism and muscle 
contraction, further supports the validity of the proposed model and provides us with novel 
biological targets. This last achievement represents an important step forward for the 
development of more specific drugs to treat LMNA-CMP.  
In this Thesis we demonstrated the robust association between the LMNA mutations and the 
observed patient phenotype. However, some limitations are yet to be overcome.  
Among them, the immature state of iPSCs-derived CMs represent a critical issue and their 
management in late-onset diseases is still debated.  
In addition to the consideration of the iPSC-CMs maturation stage, there is another limitation 
of this study. It would be very interesting to investigate the transcriptional effect of the 
LaminA/C mutations through whole-genome approach. Indeed, a global transcriptional 
reprogramming is likely to occur in CMs in presence of mutated LaminA/C, altering 
regulation of key genes in disease-progress (i.e. genes involved in contractile machinery and 
cell metabolism). However, genome-wide investigations and genome conformation analysis 
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